# Large-scale interaction profiling of PDZ domains through proteomic peptide-phage display using human and viral phage peptidomes

Ylva Ivarsson<sup>a,1</sup>, Roland Arnold<sup>a</sup>, Megan McLaughlin<sup>a,b</sup>, Satra Nim<sup>a</sup>, Rakesh Joshi<sup>c</sup>, Debashish Ray<sup>a</sup>, Bernard Liu<sup>d</sup>, Joan Teyra<sup>a</sup>, Tony Pawson<sup>d,2</sup>, Jason Moffat<sup>a,b</sup>, Shawn Shun-Cheng Li<sup>c</sup>, Sachdev S. Sidhu<sup>a,c,3</sup>, and Philip M. Kim<sup>a,b,e,3</sup>

<sup>b</sup>Department of Molecular Genetics, <sup>e</sup>Department of Computer Science, <sup>a</sup>Donnelly Centre, University of Toronto, Toronto, ON, Canada M5S 3E1; <sup>c</sup>Department of Biochemistry, Western University, London, ON, Canada N6A 5C1; and <sup>d</sup>Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5

Edited\* by William F. DeGrado, University of California at San Francisco School of Pharmacy, San Francisco, CA, and approved January 6, 2014 (received for review July 2, 2013)

The human proteome contains a plethora of short linear motifs (SLiMs) that serve as binding interfaces for modular protein domains. Such interactions are crucial for signaling and other cellular processes, but are difficult to detect because of their low to moderate affinities. Here we developed a dedicated approach, proteomic peptide-phage display (ProP-PD), to identify domain-SLiM interactions. Specifically, we generated phage libraries containing all human and viral C-terminal peptides using custom oligonucleotide microarrays. With these libraries we screened the nine PSD-95/ Dlg/ZO-1 (PDZ) domains of human Densin-180, Erbin, Scribble, and Disks large homolog 1 for peptide ligands. We identified several known and putative interactions potentially relevant to cellular signaling pathways and confirmed interactions between fulllength Scribble and the target proteins β-PIX, plakophilin-4, and guanylate cyclase soluble subunit  $\alpha$ -2 using colocalization and coimmunoprecipitation experiments. The affinities of recombinant Scribble PDZ domains and the synthetic peptides representing the C termini of these proteins were in the 1- to 40-µM range. Furthermore, we identified several well-established host-virus proteinprotein interactions, and confirmed that PDZ domains of Scribble interact with the C terminus of Tax-1 of human T-cell leukemia virus with micromolar affinity. Previously unknown putative viral protein ligands for the PDZ domains of Scribble and Erbin were also identified. Thus, we demonstrate that our ProP-PD libraries are useful tools for probing PDZ domain interactions. The method can be extended to interrogate all potential eukaryotic, bacterial, and viral SLiMs and we suggest it will be a highly valuable approach for studying cellular and pathogen-host protein-protein interactions.

here are an estimated 650,000 protein-protein interactions in a human cell (1). These interactions are integral to cellular function and mediate signaling pathways that are often misregulated in cancer (2) and may be hijacked by viral proteins (3). Commonly, signaling pathways involve moderate affinity interactions between modular domains and short linear motifs (SLiMs; conserved 2- to 10-aa stretches in disordered regions) (4) that are difficult to capture using high-throughput methods, such as yeast two-hybrid (Y2H) or affinity-purification mass spectrometry (AP/MS) but can be identified using peptide arrays, splitprotein systems (5, 6), or peptide-phage display (7-10). A major limitation of peptide arrays is coverage, because the number of potential binding peptides in the proteome is orders of magnitude larger than what can be printed on an array. Conventional phage libraries display combinatorially generated peptide sequences that can identify biophysically optimal ligands of modular domains but this approach can exhibit a hydrophobic bias and may not be ideal for detecting natural binders (11). Thus, there is a need for alternative approaches for identification of relevant domain-SLiMs interactions.

Here, we report an approach that solves both the problem of coverage and the problem of artificial binders. We take advantage of microarray-based oligonucleotide synthesis to construct custom-made peptide-phage libraries for screening peptideprotein interactions, an approach we call proteomic peptidephage display (ProP-PD) (Fig. 1). This process is similar in concept to the method for autoantigen discovery recently proposed by Larman et al. (12). In this earlier work, a T7 phage display library comprising 36-residue overlapping peptides covering all ORFs in the human genome was used to develop a phage immunoprecipitation sequencing methodology for the identification of autoantigens. A more general application of the library for the identification of protein-peptide interactions was introduced, but not explored in depth. We here establish that ProP-PD is a straightforward method for the identification of potentially relevant ligands of peptide binding domains. Our approach is based on the filamentous M13 phage, which is highly suited for efficient screening of peptide binding domains (13). The main advantage of our display system is that it is nonlytic and highly validated; random M13 phage-displayed peptide libraries have been used to map binding specificities of hundreds of diverse modular domains (7, 8, 14–16). We showcase our approach by identifying interactions of PSD-95/Dlg/ZO-1 (PDZ) domains.

## Significance

Although knowledge about the human interactome is increasing in coverage because of the development of high-throughput technologies, fundamental gaps remain. In particular, interactions mediated by short linear motifs are of great importance for signaling, but systematic experimental approaches for their detection are missing. We fill this important gap by developing a dedicated approach that combines bioinformatics, custom oligonucleotide arrays and peptide-phage display. We computationally design a library of all possible motifs in a given proteome, print representatives of these on custom oligonucleotide arrays, and identify natural peptide binders for a given protein using phage display. Our approach is scalable and has broad application. Here, we present a proof-of-concept study using both designed human and viral peptide libraries.



Author contributions: Y.I., S.S.S., and P.M.K. designed research; Y.I., R.A., M.M., S.N., and R.J. performed research; M.M., S.N., R.J., D.R., B.L., T.P., J.M., and S.S.-C.L. contributed new reagents/analytic tools; Y.I., R.A., J.T., S.S.S., and P.M.K. analyzed data; and Y.I., S.S.S., and P.M.K. wrote the paper.

The authors declare no conflict of interest.

<sup>\*</sup>This Direct Submission article had a prearranged editor.

Freely available online through the PNAS open access option.

<sup>&</sup>lt;sup>1</sup>Present address: Department of Chemistry–BMC, Uppsala University, S-752 37 Uppsala, Sweden.

<sup>&</sup>lt;sup>2</sup>Deceased August 7, 2013.

<sup>&</sup>lt;sup>3</sup>To whom correspondence may be addressed. E-mail: sachdev.sidhu@utoronto.ca or pi@ kimlab.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1312296111/-/DCSupplemental.



Fig. 1. Overview of the ProP-PD. The human and viral ProP-PD libraries were designed to contain over 50,000 or 10,000 C-terminal heptapeptides, respectively. Oligonucleotides encoding the sequences were printed on microarray slides, PCR-amplified, and cloned into a phagemid designed for the display of peptides fused to the C terminus of the M13 major coat protein P8. The libraries were used in binding selections with PDZ domains and the selected pools were analyzed by next-generation sequencing on the Illumina platform.

The PDZ family is one of the largest domain families in the human proteome, with about 270 members that typically interact with C-terminal peptides (class I binding motif: x-S/T-x- $\Phi$ -COO-, class II: x- $\Phi$ -x- $\Phi$ -COO-) (17) but also with internal peptide stretches and phosphoinositides (18, 19). PDZ-peptide interactions have been extensively analyzed by distinct experimental efforts, such as peptide-phage display (7, 20), peptide arrays (9, 21, 22), and split-ubiquitin membrane Y2H (23), as well as by computational approaches (24–28). Furthermore, the PDZ family has been shown to be the target of viral hijacking, whereby virus proteins mimic the C termini of human proteins to exploit these interactions (29). Thus, the PDZ family offers an excellent model system for validation of the ProP-PD approach.

We created ProP-PD libraries displaying all known human and viral C-terminal peptide sequences and used these to identify binding partners for the nine PDZ domains of Densin-180, Erbin, Scribble, and disk large homolog 1 (DLG1) (Fig. 1). These proteins have crucial roles in the postsynaptic density of excitatory neuronal synapses, in the establishment of adherens and tight junctions in epithelial cells, and in the regulation of cell polarity and migration (30–32). Additionally, both Scribble and DLG1 are known targets of viral proteins (33, 34). Using the ProP-PD libraries we identified known and novel human and viral ligands and validated candidates in vivo and in vitro. Our results demonstrate that ProP-PD is a powerful approach for the proteomic screening of human and viral targets. Future studies with larger libraries tiling the complete disordered regions of any proteome can be envisioned, as the technology is highly scalable.

#### Results

Library Design and Construction. We designed a human peptide library containing 50,549 heptamer C-terminal sequences, corresponding to 75,797 proteins, including isoforms and cleaved sequences (Dataset S1), reported in the RefSeq, TopFind, and ENSEMBL databases (Status December 2011) (Fig. 2A). The peptides only listed in TopFind represent experimentally validated alternative C termini resulting from proteolytic cleavage events (35). Four percent of the entries map to more than one protein because they have identical C-terminal peptide sequences. In addition, we designed a library of all known viral protein C termini, containing the 10,394 distinct viral protein C termini found in Swissprot corresponding to 15,995 viral proteins (Fig. S1 and Dataset S2). Oligonucleotides encoding the peptides flanked by annealing sites were printed on custom microarrays, PCR-amplified, and used in combinatorial mutagenesis reactions to create libraries of genes encoding for peptides fused to the C terminus of the M13 major coat protein P8 in a phagemid vector (Fig. 1) (36). In our hybrid M13 phage systems, the phage particle contains all of the wild-type coat proteins with the addition of the fusion protein for display. The system has previously been

Ivarsson et al.

optimized for efficient display of C-terminal peptides (37). The display level of the fusion protein is expected to be between 5% and 40% of the about 2,700 copies of the P8 protein on the phage particle (38). The avidity of the displayed peptides ensures the capture of transient domain–SLiMs interactions.

From each obtained oligonucleotide microarray we constructed two distinct phage libraries that were used in replicate screens against the target domain. Deep sequencing of the naïve libraries confirmed the presence of more than 80% and 90% of the designed human and viral sequences, respectively. The majority of the incorporated sequences were designed wild-type peptides but about 30% of the sequences had mutations (Fig. 2B). The mutations may arise from the oligonucleotide synthesis, the copying of the oligonucleotides of the microarray surface, the PCR amplification of the oligonucleotide library, or during the phage library construction and amplification. Indeed, the M13 phage has a mutation rate of 0.0046 per genome per replication event (39). The percentage of mutations in our libraries is lower than what was observed in the previous study by Larman et al. (12). Moreover, each library contained  $10^8$  to  $10^9$  unique members, which far exceeded the number of unique C-terminal peptides encoded by the DNA arrays, and thus, the mutations did not compromise coverage of our designed library sequences.

Analysis of the ProP-PD Selection Data. The replicate ProP-PD libraries were used to capture binders for nine recombinant GSTtagged PDZ domains (Densin-180 PDZ; Erbin PDZ; Scribble PDZ1, PDZ2, PDZ3, and PDZ4; and DLG1 PDZ1, PDZ2, and PDZ3) following five rounds of selection. The selections were successful as judged by pooled phage ELISA, except for Scribble PDZ4, which has previously been found to fail in conventional C-terminal peptide-phage display, suggesting that this domain may not recognize C-terminal peptide ligands or that it is not functional when immobilized on the plastic surface (7, 40). Resultant phage pools were analyzed by next-generation sequencing. To define a high interest set of peptides that interact with the PDZ domains, we filtered as follows: (i) discarded mutated sequences, (ii) required a minimum threshold of read count (as indicated in Fig. 3A), and (iii) selected peptides found in either Uniprot/Swissprot or RefSeq (April 2013).

For the replicate libraries, the overall correlation between the selected peptides for all domains was high (Fig. 3B) ( $r^2 = 0.8$  for all data), providing an estimate of the reproducibility of the procedure. Looking at individual domains, we found that the correlations between the replicate selections were lower in some cases (Scribble PDZ2 and PDZ3, DLG1 PDZ2  $0.5 < r^2 < 0.7$ ) than in others (Scribble PDZ1, Erbin PDZ, and DLG1 PDZ3,  $r^2 = 0.99$ ). It thus appears to be good practice to construct more than one library for each design to ensure good coverage of the sequence space.

**Comparison with Conventional Peptide-Phage Display.** To compare the data obtained from the ProP-PD selections with results from conventional peptide-phage display, we derived position weight matrices (PWMs) based on the ProP-PD data and found good overall agreement with PWMs derived from random peptide-phage display libraries of a previous study (7) (Fig. S2). The



**Fig. 2.** Library design and quality. (*A*) Histogram showing the number of entries taken from distinct databases to design the human C-terminal ProP-PD library. (*B*) Pie chart showing the composition of the libraries as determined by deep sequencing.



Fig. 3. Analysis of the ProP-PD selection data. (A) Assignment of cut-off values. The histogram shows the deep-sequencing data of the phage pool selected for DLG1 PDZ2 from the human ProP-PD library. The gray dotted line indicates the assigned cut-off value, which is after the peak of the nonspecific peptides. (B) Correlation between selections against replicate libraries using all sequencing data when applicable (Tables S1 and S2). The data from the selections against the human libraries are in black and the data from the viral libraries are in gray. Most of the points are in the low count range and clustered in the lower left corner. (C) Comparisons between ProP-PD data and predictions based on PWMs derived from conventional phage display for domains with more than two ProP-PD ligands. The datapoints are shown as red circles, except the outliers (defined as PWM rank > 1,000) that are shown as black dots. The blue line represent is the linear fit of the data, excluding outliers. (D) Overlaps between identified ligands and interactions reported in the domino and BioGRID databases. For Scribble and DLG1 we pooled the results for the ProP-PD selections for their respective PDZ1, PDZ2, and PDZ3 domains.

ProP-PD-based PWMs were generally less hydrophobic, as evidenced by calculation of their accumulated hydrophobicity values. We further investigated if conventional phage display would have identified proteins containing the C-terminal sequences obtained from ProP-PD (Fig. 3C and Table S1). There is good agreement between the two systems for Erbin, DLG1 PDZ2, and PDZ3; however, clear differences were observed for Scribble PDZ1, PDZ2, and PDZ3 targets (Fig. 3C). For Erbin PDZ there is one notable outlier (YYDYTDV) that lacks the C-terminal [T/S]WV motif, which is otherwise the hallmark of the ligands of this domain. For Scribble PDZ1 the three highest ranked ProP-PD ligands are captured by the PWM predictions, but not the lower ranked peptides.

There are several discrepancies between the PWM-based predictions and the ProP-PD data for Scribble PDZ2 and PDZ3. For example, for Scribble PDZ2, the first (GSPDSWV) and fifth (ASPDSWV) highest ProP-PD ligand score badly in the PWMbased predictions, which may in part be explained by the S at position -2 that is not represented in the PWM used for predictions. Among the outliers of Scribble PDZ3 we note the IRETHLW peptide, which appears to contain a cryptic PDZ class I motif with a shift of one amino acid, as previously suggested for other PDZ ligands (25). Other outliers (ASFWETS, GDLFSTD, and THWRETI) do not contain typical class I binding motifs and are therefore missed by the PWM-based predictions.

Comparison Between Human ProP-PD Data and Known Ligands. We compared the overlap between our identified putative human ligands with the physical interactions reported in the BioGRID and DOMINO databases (excluding high-throughput AP/MS data to avoid comparing binary interactions with complexes). The overlaps (Fig. 3D) are rather low, and there are two likely reasons for this. First, BioGRID (and other related databases) do not yet annotate the domains/motifs mediating the interactions. Hence, the interactions reported therein may be mediated by other parts of the protein not represented in this study. Second, the coverage of DOMINO is known to be relatively low (41). A more extensive literature search provided support for about 50% of the interactions for the PDZ domains of Erbin, DLG1, and Densin-180, suggesting that a high proportion of the ligands identified by ProP-PD are relevant (Fig. 3A and Table S1). Curiously, we found support for only 5 of the 36 ligands identified for the Scribble PDZ domains and therefore attempted to validate some of these new interactions using in vitro affinity determination and cell-based assays.

Validation of Human Scribble Ligands in Vitro. We determined in vitro affinities using fluorescence polarization assays (Table 1). We synthesized fluorescein-labeled peptides for the first ranked ligands for each of the Scribble PDZ domains (PDZ1: RFLETKL and AWDETNL, PDZ2: GSPDSWV and VQRHTWL, PDZ3: VQRHTWL and AWDETNL). The affinities (Table 1) were in the low micromolar range (1–40  $\mu$ M), which is typical for PDZ domain-mediated interactions (42) and similar to what have been observed for synthetic ligands derived from combinatorial phage libraries (7, 20).

Furthermore, we measured affinities for additional Scribble PDZ3 interactions to investigate if there was a correlation between affinities and the sequencing counts (covering a range of 0-10,000 counts). The peptides (Table 1) conform to a class I binding motif (x-S/T-x- $\Phi$ -COO-), with the exceptions of the IRETHLW and the ASFWETS peptides, as discussed previously. There is a weak correlation  $(r^2 = 0.36)$  between the logarithm of the sequencing counts and the affinities (Fig. S3), suggesting that ProP-PD data can be used in a semiquantitative manner, similar to intensities from peptide arrays. The observed counts can be influenced by factors other than affinities-such as phage growth rates (43), different display levels, and biases in amplicon PCR (44)-but such confounding effects can be minimized by exceedingly high library coverage during selections, using a display system with minimal growth bias for different clones and optimizing PCR conditions for linear amplification. From the linear fit we estimate that peptides with affinities weaker than 20 µM may be lost, and the GSPDSWV peptide  $(K_{\rm d} = 22 \ \mu {\rm M})$  was indeed not retrieved in the sequencing data from this selection. We failed to detect an interaction between Scribble PDZ3 and the ASFWETS peptide in the concentration range used, indicating that it is a false-positive hit.

Validation of Scribble Ligands in Vivo. For additional validations we performed colocalization and coimmunoprecipitation (Co-IP) experiments using N-terminally GFP-tagged Scribble and N-terminally Flag-tagged full-length target proteins containing six of the peptides used for affinity determinations, namely  $\beta$ -PIX (ARGH7, positive control), PKP4,  $\beta$ -catenin (CTNB1), mitogenactivated kinase 12 (MK12), guanylate cyclase soluble subunit

Table 1. Dissociation constants of the PDZ domains of Scribble with selected peptides as determined using synthetic fluorescein-labeled peptides

									<i>K</i> <sub>D</sub> (μM)	
Protein				Peptide	9			PDZ1	PDZ2	PDZ3
Human	-6	-5	_4	-3	-2	-1	0			
B7Z2Y1	R	F	L	Е	Т	К	L	2.1 ± 0.2	29 ± 5	5.8 ± 0.6
ARHG7	Α	W	D	Е	Т	Ν	L	2.3 ± 0.3	17 ± 2	3.5 ± 0.2
NXPE2	V	Q	R	н	Т	W	L	NA	5 ± 1	7 ± 2
PKP4	G	S	Р	D	S	W	V	NB	37 ± 7	22 ± 5
DNM1L	I	R	Е	т	н	L	W	NB	NA	1.1 ± 0.4
MK12	V	S	К	Е	Т	Р	L	NA	NA	5.0 ± 0.5
GCYA2	F	L	R	Е	Т	S	L	NA	NA	10 ± 2
CTNB1	Α	W	F	D	Т	D	L	NA	NA	8.5 ± 2
MET	Α	S	F	W	Е	т	S	NA	NA	NB
Viral										
TAX HTL1L	Н	F	Н	Е	Т	Е	V	NA	7 ± 2	2.5 ± 0.7

NA, not available as the dissociation constants were not determined; NB, no binding under conditions used. No binding was observed with the scrambled NATWLED peptide used as negative control.

 $\alpha$ -2 (GCYA2), and dynamin-1-like protein (DNM1L). Upon transient overexpression in HEK293T cells, Scribble clearly colocalized with ARGH7, GCYA2, and PKP4 (Fig. 4A) at distinct subcellular sites. Notably, Scribble was targeted to distinct vesicular structures when coexpressed with ARGH7 and GCYA2 but enriched at filamentous structures when expressed with PKP4. These interactions were further supported by Co-IP experiments (Fig. 4). Some colocalization was noted between CTNB1 and Scribble (Fig. S4), but we failed to confirm an interaction between the two proteins through Co-IP. CTNB1 and Scribble have previously been shown to colocalize in hippocampal neurons and have been coimmunoprecipitated from neuronal lysates (45), and may thus interact under other cellular contexts. Coexpressed MK12 and Scribble were found diffused in the cytoplasm, but weak yet consistent bands were observed from their Co-IP supporting an interaction (Fig. 4B). In contrast, when Scribble was coexpressed with DNM1L, it was targeted to vesicular structures, whereas DNM1L was found to be diffused in the cells. Furthermore, the Co-IP between the two proteins was largely negative. Colocalizations and Co-IPs thus support the interactions between full-length Scribble and ARGH7, GCYA2, PKP4, and MK12 but not with DNM1L.

**Overview of Human Targets.** We created a protein–protein interaction network of the four PDZ-containing proteins with their 78 putative binding partners for a comprehensive overview of the data (Fig. S5). Consistent with previous studies and roles in cell polarity and adhesion, the network of the LAP proteins Densin-180, Erbin, and Scribble contains interactions with the catenin family members PKP4,  $\delta$ -catenin, and ARVCF (40, 46–48), whereas the DLG1 part of the network contains previously known interactions with anion transporters, potassium channels, and G protein-coupled receptors (see *SI Methods* for a detailed discussion of the network and biological relevance of the previously unknown interactions).

**Host–Virus Protein–Protein Interactions.** The viral ProP-PD library was created to identify putative interactions between viral proteins and human PDZ domains. For the PDZ domains of Scribble and DLG1, we retrieved mainly previously known interactors (*SI Methods* and Table S2) (29). We determined the affinities of the Tax-1 C-terminal peptide (HFETEV) for Scribble PDZ2 and PDZ3 and found them to be in the low micromolar range (Table 1), similar to the affinity for the human ligands.

The viral ProP-PD further suggested a set of novel host-virus protein-protein interactions listed in Table S2, including an interaction between Scribble and the rabies virus glycoprotein G, which has previously been shown to bind other PDZ proteins (41). In addition, we revealed interactions between DLG1 PDZ2 and the C termini of the cytomegalovirus protein HHRF7 and the

glycoprotein U47 of human herpes virus 6A. Finally, the ProP-PD data suggest several new ligands for Erbin PDZ, such as the Vpu protein of HIV and the Bat coronavirus envelope small membrane protein. These results show how the ProP-PD approach can be used to identify novel putative host–virus protein–protein interactions.

## Discussion

We made use of custom oligonucleotide arrays to construct defined phage display libraries comprising the entire human and viral C-terminomes found in Swissprot. We demonstrated the power of such customized peptide-phage libraries in identifying ligands of potential biological relevance using PDZ domains as model proteins. Compared with conventional phage display, the main strength of our approach is the defined search space encompassing biological ligands, which obviates the need for predictions. Next-generation sequencing of the phage pools provides a list of selected peptide sequences that are directly associated with target



proteins of potential biological relevance. We identified interactions between PDZ domains and C-termini of human proteins, and expanded the ProP-PD approach to screen for host–virus protein–protein interactions. Future studies with more extensive viral libraries can be envisioned. For example, it is possible to generate comprehensive libraries of viral species, including extensive sequence variations from strain sequencing, for the rapid screening of interactions between host proteins and virus proteins and for potential subtyping of viral strains based on their binding preferences. The method could also be extended to pathogenic bacteria that have been shown to exploit modular domains (41).

The PDZ ligands retrieved from the ProP-PD appear generally less hydrophobic than ligands derived using combinatorial phage libraries, although the affinities for the bait proteins are in the same range (7, 20). The hydrophobic bias might be explained by a bias in the M13 phage display system toward displaying hydrophobic peptides (49). Because such hydrophobic peptides are less abundant in the ProP-PD libraries, this issue is circumvented. However, the ProP-PD method has other limitations. First, it does not account for spatial or temporal separation of the ligands within cells, although it can be envisioned to filter the data for such factors. Second, ProP-PD is not suitable for tackling posttranslational modifications, which are common regulatory mechanisms of domain–SLiMs interactions (50).

ProP-PD can be compared with other methods for detection of protein-peptide interactions, such as SPOT microarrays, where defined peptides are synthesized on a cellulose membrane (10, 51). The SPOT array technique has the key advantage of allowing for studies of modifications, such as phosphorylation and acetylation, but has several disadvantages. First, the number of peptides that can be printed on a SPOT microarray is still smaller than necessary. By contrast, ProP-PD libraries scale easily and could contain all potential human binding motifs. Second, SPOT microarrays have relatively high false-positive rates, which does not appear to be the case for Prop-PD. The approach can also be compared with Y2H. Although Y2H has the advantage of screening full proteins (rather than only peptides), it has generally had both lower sensitivity and specificity for detecting domain-SLiM interactions (52). Another advantage of the ProP-PD approach over Y2H is that it is not limited to proteins that can be translocated to the nucleus. Finally, ProP-PD can be compared with AP/MS, which has the advantage of probing interactions in a cellular context. However, elusive SLiMs interactions are often not detected in these experiments. Thus, ProP-PD can be used as to complement AP/MS derived networks.

Over the last decade there has been increasing interest in intrinsically disordered regions, which are present in about 30% of human proteins (53) and are enriched in SLiMs that may serve as binding sites for target proteins. Although there are more than 100,000 SLiMs instances in the human proteome (4), the function is only known for a fraction (54). By creating ProP-PD libraries that represent all of the disordered regions of target proteomes, it will be possible to rapidly and comprehensively screen for SLiMsdomain interactions. A library of the complete human proteome has indeed already been constructed using the T7 display system, and it was validated for protein–peptide interaction screening by the identification of a known ligand for GST-tagged replication protein A2. However, other binding partners were not picked up as the target motifs were at the breakpoints between peptides, highlighting the importance of the initial design of the libraries.

As outlined by Larman et al., the ProP-PD approach can also be used for the identification of antibody epitopes, and the peptides may to some extent retain some secondary structures when expressed on the coat protein (12). This aspect is reminiscent of other studies where libraries of highly structured natural peptides have been used to identify inhibitors of proteinprotein interactions (55). Folded peptides from proteomes distinct from the target organism may be used for identification of inhibitors of specific human protein-protein interactions. The design of folded rather than disordered peptide libraries could be a possible extension of our ProP-PD approach. We believe that the ProP-PD technology can be scaled to any proteome of interest and will become a widely applicable method for the rapid proteome-wide profiling of peptide-binding modules. It will enable the unbiased search for potential biologically relevant targets for network analysis and comparative studies.

### Methods

**Design of Human and Viral ProP-PD Libraries.** The human ProP-PD library (Dataset S1) was designed by retrieving information from Ensembl62 (version GRCh37.6, built 64), RefSeq and TopFind (downloaded December 2011). The viral C-terminal library contained the nonredundant C-terminal heptapetides (Dataset S2) retrieved from Swissprot with an overview of host specificities in Fig. S1. The C-terminal peptide sequences were reverse translated using the most frequent *Escherichia coli* codons (56) and the coding sequences were flanked by primer annealing sites for PCR amplification and site-directed mutagenesis reactions.

Oligonucleotide Pool from Microarray Chip. The designed oligonucleotides were obtained on 244k microarray chips (Agilent) and copied from the microarray chips through hybridization of primers designed to anneal to the single stranded templates. The primer (GCCTTAATTGTATCGGTTTA) complementary to the 3' end of the designed oligonucleotides was dissolved (30 μM) in hybridization buffer [1 M NaCl, 10 mM Tris-HCl pH 7.5, 0.5% Trition-X100, 1 mM dithiothritol (DTT)] and allowed to hybridize to the templates for 4 h at 30 °C under rotation. Unbound primer was removed by washing with 50 mL of low-stringency wash buffer (890 mM phosphate buffer, pH 7.4, 60 mM NaCl, 6 mM EDTA, 0.5% Triton-X100) followed by 50 mL of high-stringency wash buffer (8.9 mM phosphate buffer pH 7.4, 0.6 mM NaCl, 0.06 mM EDTA, 0.5% Triton-X100). A complementary strand was synthesized through a polymerase reaction [900 μL reaction: 1× NEB buffer 2 (10 mM Tris·HCl, 10 mM MgCl<sub>2</sub>, 50 mM NaCl, 1 mM DTT, pH 7.9), 90 µg BSA, 0.1 mM of each dNTP, 54 units of T4 DNA polymerase, 75 units of Klenow Fragment (3'-5' exo-; New England Biolabs)] at 30 °C for 30 min. The newly synthesized oligonucleotides were removed from the microarray chip by incubation with 1 mL 20 mM NaOH at 65 °C for 20 min. The eluted single-stranded oligonucleotides were precipitated in Eppendorf tubes at -80 °C for 2 h by addition of 3 M sodium acetate, molecular grade glycogen, and 100% (vol/vol) ethanol [final concentrations 85 mM sodium acetate, 0.7% glycogen, 70% (vol/vol) ethanol]. The DNA was pelleted by centrifugation at 16,100  $\times$  g at 4 °C for 30 min, the supernatant removed, and the pellets washed by addition of cold 70% (vol/vol) ethanol and centrifugation at 16,100  $\times$  g at 4 °C for 5 min. The DNA pellets were allowed to dry at room temperature for 30 min and resuspended in a total volume of 40 µL water. The single-stranded oligonucleotides (1 µL for 50-µL reaction) were used as template for a PCR using Taq polymerase to amplify the library (24 cycles of 55 °C annealing, 72 °C elongation, and 98 °C denaturation). To improve coverage, the template was amplified in 16 separate reactions. The PCR products were confirmed by gel electrophoresis [2.5% (wt/vol) agarose] with SYBR Safe (Invitrogen) staining, purified on four columns of the QIAgen nucleotide removal kit and eluted in 40  $\mu$ L water from each column. The concentration of the dsDNA was estimated using PicoGreen dye (Invitrogen) and using a twofold dilution series (100-0.8  $\mu$ g/ $\mu$ L) of  $\lambda$ -phage double-stranded DNA (dsDNA, Invitrogen) as a standard. The PicoGreen dye was diluted 1:400 in TE buffer and mixed with 1 µL of dsDNA standard or PCR product in a low-fluorescence 96-well plate (Bio-Rad). The fluorescence was read in a quantitative PCR machine (Bio-Rad) (excitation 480 nm, emission 520 nm) and the sample DNA concentration was determined from the standard curve.

Library Construction and Amplification ProP-PD libraries were constructed following a modified version of a published procedure (57, 58). The PCR-amplified dsDNA (0.6  $\mu$ g) was used as primers for oligonucleotide-directed mutagenesis after removal of residual single-stranded (ssDNA) by Exol treatment (0.2 units/ $\mu$ L, 37 °C for 30 min, 85 °C for 15 min) followed by flash cooling on ice. The dsDNA was then directly 5' phosphorylated for 1 h at 37 °C in TM buffer (10 mM MgCl<sub>2</sub>, 50 mM Tris, pH 7.5) and 1 mM ATP, 5 mM DTT using a T4 polynucleotide kinase (1 unit/ $\mu$ L; New England Biolabs). The phosphorylated dsDNA was denatured and annealed (95 °C for 3 min, 50 °C for 3 min and 20 °C for 5 min) to ssDNA template [10  $\mu$ g ssDNA encoding the M13 major coat protein P8 (36) prepared as described elsewhere (57)] in TM buffer in a total volume of 250  $\mu$ L dsDNA was synthesized overnight at 20 °C by addition of 10  $\mu$ L 10 mM ATP, 10  $\mu$ L 10 mM dNTP mixture, 15  $\mu$ L 100 mM DTT, 30 Weiss units T4 DNA ligase, and 30 units T7 DNA. The DNA was

purified using a QIAquick DNA purification kit and eluted with 35  $\mu$ L water. The phagemid library was converted into a ProP-PD library by electroporation into *E. coli* SS320 cells preinfected with M13KO7 helper phage (58). The transformation efficiency was 10<sup>8</sup> to 10<sup>9</sup> transformants per reaction thus exceeding the theoretical diversity of the library by more than 1,000-fold. The phage-producing bacteria were grown over night in 500 mL 2YT (16 g Bacto tryptone, 10 g Bacto yeast extract, 5 g NaCl, per liter water) medium at 37 °C and then pelleted by centrifugation (10 min at 11,270 × g). The supernatant was transferred to a new tube and phages were precipitated by adding one-fifth volume polyethylene glycol·NaCl, [20% PEG-8000 (wt/vol), 2.5 M NaCl], incubating for 5 min at 4 °C and centrifuging at 28,880 × g at 4 °C for 20 min. The phage pellet was resuspended in 20 mL PBT (PBS, 0.05% Tween-20, 0.2% BSA), insoluble

- 1. Stumpf MP, et al. (2008) Estimating the size of the human interactome. Proc Natl Acad Sci USA 105(19):6959–6964.
- Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat Rev Drug Discov 3(4):301–317.
- Davey NE, Travé G, Gibson TJ (2011) How viruses hijack cell regulation. Trends Biochem Sci 36(3):159–169.
- 4. Davey NE, et al. (2012) Attributes of short linear motifs. Mol Biosyst 8(1):268-281.
- Shekhawat SS, Ghosh I (2011) Split-protein systems: Beyond binary protein-protein interactions. Curr Opin Chem Biol 15(6):789–797.
- Lam MH, Stagljar I (2012) Strategies for membrane interaction proteomics: no mass spectrometry required. Proteomics 12(10):1519–1526.
- 7. Tonikian R, et al. (2008) A specificity map for the PDZ domain family. *PLoS Biol* 6(9): e239.
- Tonikian R, Zhang Y, Boone C, Sidhu SS (2007) Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. *Nat Protoc* 2(6): 1368–1386.
- Stiffler MA, et al. (2007) PDZ domain binding selectivity is optimized across the mouse proteome. Science 317(5836):364–369.
- Breitling F, Nesterov A, Stadler V, Felgenhauer T, Bischoff FR (2009) High-density peptide arrays. *Mol Biosyst* 5(3):224–234.
- Luck K, Travé G (2011) Phage display can select over-hydrophobic sequences that may impair prediction of natural domain-peptide interactions. *Bioinformatics* 27(7):899–902.
- 12. Larman HB, et al. (2011) Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 29(6):535–541.
- 13. McLaughlin ME, Sidhu SS (2013) Engineering and analysis of peptide-recognition domain specificities by phage display and deep sequencing. *Methods Enzymol* 523:327–349.
- Xin X, et al. (2013) SH3 interactome conserves general function over specific form. Mol Syst Biol 9:652.
- Vetter SW (2013) Phage display selection of peptides that target calcium-binding proteins. *Methods Mol Biol* 963:215–235.
- Pande J, Szewczyk MM, Grover AK (2010) Phage display: Concept, innovations, applications and future. *Biotechnol Adv* 28(6):849–858.
- Luck K, Charbonnier S, Travé G (2012) The emerging contribution of sequence context to the specificity of protein interactions mediated by PDZ domains. *FEBS Lett* 586(17): 2648–2661.
- Ivarsson Y, et al. (2013) Prevalence, specificity and determinants of lipid-interacting PDZ domains from an in-cell screen and in vitro binding experiments. PLoS ONE 8(2):e54581.
- Wawrzyniak AM, Vermeiren E, Zimmermann P, Ivarsson Y (2012) Extensions of PSD-95/discs large/ZO-1 (PDZ) domains influence lipid binding and membrane targeting of syntenin-1. *FEBS Lett* 586(10):1445–1451.
- Sharma SC, Memic A, Rupasinghe CN, Duc AC, Spaller MR (2009) T7 phage display as a method of peptide ligand discovery for PDZ domain proteins. *Biopolymers* 92(3):183–193.
- Boisguerin P, et al. (2004) An improved method for the synthesis of cellulose membrane-bound peptides with free C termini is useful for PDZ domain binding studies. Chem Biol 11(4):449–459.
- Wiedemann U, et al. (2004) Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptides. J Mol Biol 343(3): 703–718.
- Gisler SM, et al. (2008) Monitoring protein-protein interactions between the mammalian integral membrane transporters and PDZ-interacting partners using a modified split-ubiquitin membrane yeast two-hybrid system. *Mol Cell Proteomics* 7(7): 1362–1377.
- Chen JR, Chang BH, Allen JE, Stiffler MA, MacBeath G (2008) Predicting PDZ domainpeptide interactions from primary sequences. Nat Biotechnol 26(9):1041–1045.
- 25. Gfeller D, et al. (2011) The multiple-specificity landscape of modular peptide recognition domains. *Mol Syst Biol* 7:484.
- 26. Hui S, Xing X, Bader GD (2013) Predicting PDZ domain mediated protein interactions from structure. *BMC Bioinformatics* 14:27.
- 27. Kim J, et al. (2012) Rewiring of PDZ domain-ligand interaction network contributed to eukaryotic evolution. *PLoS Genet* 8(2):e1002510.
- Smith CA, Kortemme T (2010) Structure-based prediction of the peptide sequence space recognized by natural and synthetic PDZ domains. J Mol Biol 402(2):460–474.
- Javier RT, Rice AP (2011) Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses. J Virol 85(22):11544–11556.
- Feng W, Zhang M (2009) Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density. *Nat Rev Neurosci* 10(2):87–99.

debris was removed by centrifugation and the library was stored at -20 °C in 20% (vol/vol) glycerol. The naïve libraries were deep sequenced using the Illumina platform (*SI Methods* and Fig. S6). The library was reamplified in *E. coli* SS320 cells in presence of 0.4 M IPTG.

**ProP-PD Selections and Validation Experiments.** Selections and analyses were carried out at 4 °C essentially as described by Ernst et al. (59). Similarly, peptide synthesis, affinity measurements, and Co-IPs were carried out using standard protocols. Detailed descriptions are given in *SI Methods*.

ACKNOWLEDGMENTS. This work was supported in part by an Ontario Genomics Institute SPARK grant (to P.M.K.), and Canadian Institutes of Health Research Grants MOP-123526 and MOP-93684 (to P.M.K. and S.S.S.).

- Harris BZ, Lim WA (2001) Mechanism and role of PDZ domains in signaling complex assembly. J Cell Sci 114(Pt 18):3219–3231.
- Hatzfeld M (2005) The p120 family of cell adhesion molecules. Eur J Cell Biol 84(2–3): 205–214.
- Lee SS, Weiss RS, Javier RT (1997) Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the *Drosophila* discs large tumor suppressor protein. *Proc Natl Acad Sci USA* 94(13):6670–6675.
- Nakagawa S, Huibregtse JM (2000) Human scribble (Vartul) is targeted for ubiquitinmediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. *Mol Cell Biol* 20(21):8244–8253.
- Lange PF, Overall CM (2011) TopFIND, a knowledgebase linking protein termini with function. Nat Methods 8(9):703–704.
- Fuh G, et al. (2000) Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display. J Biol Chem 275(28):21486–21491.
- Held HA, Sidhu SS (2004) Comprehensive mutational analysis of the M13 major coat protein: Improved scaffolds for C-terminal phage display. J Mol Biol 340(3):587–597.
- 38. Malik P, et al. (1996) Role of capsid structure and membrane protein processing in determining the size and copy number of peptides displayed on the major coat protein of filamentous bacteriophage. J Mol Biol 260(1):9–21.
- Drake JW (1991) A constant rate of spontaneous mutation in DNA-based microbes. Proc Natl Acad Sci USA 88(16):7160–7164.
- Zhang Y, et al. (2006) Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families. J Biol Chem 281(31):22299–22311.
- Ceol A, et al. (2007) DOMINO: A database of domain-peptide interactions. Nucleic Acids Res 35(Database issue):D557–D560.
- Jemth P, Gianni S (2007) PDZ domains: Folding and binding. *Biochemistry* 46(30): 8701–8708.
- Thomas WD, Golomb M, Smith GP (2010) Corruption of phage display libraries by target-unrelated clones: Diagnosis and countermeasures. *Anal Biochem* 407(2): 237–240.
- 44. Aird D, et al. (2011) Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries. *Genome Biol* 12(2):R18.
- Sun Y, Aiga M, Yoshida E, Humbert PO, Bamji SX (2009) Scribble interacts with betacatenin to localize synaptic vesicles to synapses. *Mol Biol Cell* 20(14):3390–3400.
- Laura RP, et al. (2002) The Erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of delta-catenin and ARVCF. J Biol Chem 277(15):12906–12914.
- Izawa I, et al. (2002) ERBIN associates with p0071, an armadillo protein, at cell-cell junctions of epithelial cells. *Genes Cells* 7(5):475–485.
- Appleton BA, et al. (2006) Comparative structural analysis of the Erbin PDZ domain and the first PDZ domain of ZO-1. Insights into determinants of PDZ domain specificity. J Biol Chem 281(31):22312–22320.
- Krumpe LR, et al. (2006) T7 lytic phage-displayed peptide libraries exhibit less sequence bias than M13 filamentous phage-displayed peptide libraries. *Proteomics* 6(15):4210–4222.
- Van Roey K, Dinkel H, Weatheritt RJ, Gibson TJ, Davey NE (2013) The switches.ELM resource: A compendium of conditional regulatory interaction interfaces. *Sci Signal* 6(269):rs7.
- Volkmer R (2009) Synthesis and application of peptide arrays: Quo vadis SPOT technology. ChemBioChem 10(9):1431–1442.
- Davey NE, Edwards RJ, Shields DC (2010) Computational identification and analysis of protein short linear motifs. Front Biosci 15:801–825.
- Dunker AK, et al. (2008) The unfoldomics decade: An update on intrinsically disordered proteins. BMC Genomics 9(Suppl 2):S1.
- Dinkel H, et al. (2012) ELM—The database of eukaryotic linear motifs. Nucleic Acids Res 40(Database issue):D242–D251.
- Watt PM (2006) Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat Biotechnol 24(2):177–183.
- Nakamura Y, Gojobori T, Ikemura T (2000) Codon usage tabulated from international DNA sequence databases: Status for the year 2000. Nucleic Acids Res 28(1):292.
- Rajan S, Sidhu SS (2012) Simplified synthetic antibody libraries. Methods Enzymol 502: 3–23.
- Sidhu SS (2000) Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 11(6):610–616.
- Ernst A, et al. (2010) Coevolution of PDZ domain-ligand interactions analyzed by high-throughput phage display and deep sequencing. *Mol Biosyst* 6(10):1782–1790.

## **Supporting Information**

## Ivarsson et al. 10.1073/pnas.1312296111

## SI Methods

**Protein Purifications.** Overnight cultures of GST and GST-PDZ (protein-95/disks large/zonula occludens-1) fusion proteins were used to inoculate 50 mL autoinducing MagicMedia (Invitrogen) supplemented with 25  $\mu$ g/mL kanamycin and were grown for 24 h at 37 °C with shaking. The bacteria were pelleted (8,000 rpm, 10 min), stored overnight at 20 °C, and purified using glutathione affinity resin (GE Healthcare). The coding regions were as described in Tonikian et al. (1).

Phage Selections. In brief, proteins were coated in 96-well Maxisorp microtiter plates (NUNC) overnight (15 µg/mL protein in 100 µL PBS per well). For the first two rounds of selection, three wells were used for each library, whereas a single well was used for the following rounds. Parallel plates were coated with GST alone to remove nonspecific binders by preselection. The next day, wells were blocked with BSA for 2 h with blocking buffer (PBS, 0.2% BSA). Phage pools representing the naïve peptide library were diluted 10-fold in PBS, precipitated with polyethylene glycol-NaCl [4% PEG-800 (wt/vol) and 0.5 M NaCl] and resuspended to a final concentration of  $10^{12}$  cfu/mL in PBT. In the first selection round, 100 µL of the phage pool representing the naïve peptide library was added to each well of the preselection plate, incubated for 1 h, transferred to the target plate, and incubated for an additional 2 h. The plate was washed four times with cold wash buffer (PBS, 0.5% Tween-20) and bound phage was eluted by direct infection into bacteria by the addition of 100  $\mu$ L of log-phase Escherichia coli SS230 ( $A_{600}$  = 0.8) in 2YT to each well and incubation for 30 min at 37 °C with shaking. M13K07 helper phage (New England Biolabs) was added to a final concentration of  $10^{10}$  phage per milliliter to enable phage production, and the cultures were incubated for 45 min at 37 °C with shaking. The cultures were transferred to 20 mL of 2YT supplemented with kanamycin (25 µg/mL), carbenicillin (100 µg/mL), and isfopropyl-β-D-thiogalactopyranoside (IPTG; 0.4 mM), and shaken overnight at 37 °C. The bacteria was pelleted by centrifugation (10 min,  $17,090 \times g$ ), the supernatant transferred to a new tube, and phage particles were precipitated by addition of one-fifth volume of polyethylene glycol NaCl, incubated at 4 °C for 5 min, and centrifuged at  $28,880 \times g$  for 20 min. The supernatant was removed and the phage pellet was resuspended in 2 mL of PBT and then used for the next round of selection. The selections were carried out for five rounds and the progress followed by analyzing aliquots of phage supernatants in a phage ELISA (2).

The phage pools of rounds three to five and the naïve phage libraries were barcoded for Illumina sequencing as outlined by McLaughlin and Sidhu (3). Briefly, undiluted amplified phage pools (5  $\mu$ L) were used as templates for 24 cycles of 50  $\mu$ L PCR reactions using unique combinations of barcoded primers for each reaction (0.5  $\mu$ M each; for sequences of amplicon and barcodes see ref. 3) and using Phusion High Fidelity DNA polymerase (New England Biolabs) using maximum polymerase and primer concentrations. The PCR products were confirmed by gel electrophoresis (2% agarose gel) of 1  $\mu$ L of PCR products.

The amount of the DNA amplicons was normalized by PEG/ NaCl precipitation in a 96-well plate using a limiting amount of Ampure XP magnetic beads (Beckman Coulter). The magnetic beads were diluted 16-fold in PEG/NaCl and 100  $\mu$ L of this solution was mixed by pipetting with 40  $\mu$ L PCR product, incubated at room temperature for 20 min and then on a magnetic plate for 5 min to collect the beads. The supernatant was removed and the beads were washed twice with 70% EtOH, dried for 20 min at room temperature, and eluted by addition of 20 µL TE buffer (10 mM Tris, pH 8.0, and 0.1 mM EDTA). The normalized PCR amplicons were pooled (15 µL per reaction) and concentrated using two columns of a QIAquick PCR purification kit. The pooled amplicons were run on 2% agarose gel (80 V for 30 min), excised, and purified on a column of a QIAquick gel extraction kit using a modified protocol that uses extended incubation at room temperature instead of heating in Buffer QG (4). The bound DNA was eluted with 30 µL TE buffer. The concentration of the DNA was estimated picogreen dye as previously described. The PCR amplicons (~3 mg) were sent to Cofactor Genomics (Saint Louis, MO) for deep sequencing (Illumina Miseq; paired end 150 base reads, 20% PhiX). The obtained sequencing reads were filtered by discarding reads with an average PHRED quality score <35 (99.95% sequencing accuracy) or having a minimal nucleotide position score lower than 26.

Analysis of the Naïve Libraries. The quality of the proteomic peptide-phage display (ProP-PD) libraries were assessed from the deep-sequencing data by estimating the percent of starting templates, point mutations, and frame-shift mutations. The frequency of point mutations was estimated by assigning for each mutated sequence the most similar peptide sequence in the library design (denoted as parental sequence) and counting the amount of mutations as differences between the parental and mutated sequences on the DNA level. Frame-shifts were detected by aligning the DNA sequence of each mutated sequence to all sequences in the library design on DNA level using the Smith Waterman implementation provided by JAligner (parameters: identity matrix, gap opening penalty -5, gap extension -1).

Processing of Data from the Selections. The sequencing data contains selected wild-type parental peptides as well as mutant versions thereof (Fig. S6). To retrieve relevant peptides, we filtered the data for peptides occurring in the original library designs. To remove the noise we plotted histograms of the peptide frequencies (after matching to the actual library design) and manually assigned cut-off values after the prominent peak representing spurious binders after visual inspection. To focus on relevant peptides from the human ProP-PD, we subdivided the library entries into three groups based on the data available in April 2013 into a "high interest" set of true C termini comprising sequences that are in addition to either RefSeq from 2010 or Ensembl62 [also contained in one of either RefSeq or Uniprot in their 2013 versions (excluding sequences annotated as fragmentary)], a "proteolytic set" with an experimental support for a cleavage event listed in the TopFind database, and a "low interest" set with Ensembl62 entries not matching the two other sets. We filtered for peptides found in the high interest set (Table S1) and list identified targets from the low and medium interest sets in Table S3. To obtain viral targets of interest from the deep-sequencing data (Table S2) we assigned cut-off values to remove nonspecific peptides and filtered the data by removing three hits that did not originate from viruses targeting higher eukarvotes.

**Comparison with Conventional Phage Display.** Position weight matrices (PWMs) were generated using the MUSI software (5) with standard settings and without realignment of the C termini. For comparison between human targets predicted using conventional

phage display, a set of 7mer and of 10mer PWMs were calculated from the Tonikian et al. (1) data using MUSI. To compare the hydrophobicity of the retrieved ligands we calculated for the heptamer PWMs (from ProP-PD and randomized phage display, respectively), an accumulated hydrophobicity value as the sum of each amino acid hydrophobicity weight multiplied by each amino acid normalized frequency in the PWM matrix over each position (6) (Fig. S2). To compare if ProP-PD ligands would have been predicted by conventional methods, we used the 10mer PWMs based on Tonikian's data to scan a human library equivalent to the high interest set of our design using MOTIPs (7) and ranked the target peptides from 1 and up. Sequences with identical scores were ranked equally.

Peptide Synthesis. Peptides (Table 1) were synthesized using a Multipep synthesizer (Intavis AG Bioanalytical Instruments) on Wang resins (p-benzyloxybenzyl alcohol resin; AnaSpec) using 9-Fluorenyl methoxycarbonyl chemistry, with longer incubation or multiple cycles to conjugate the first C-terminal amino acid in the presence of 4-Dimethylaminopyridine (Sigma Aldrich). N-hydroxysuccinimide fluorescein (Pierce) was used to tag the N termini of the peptides with a fluorescent label. A 6-aminohexanoic acid moiety (AnaSpec) was used as a linker to separate the peptide from the fluorescein label to mitigate potential steric hinderance of protein-peptide interactions.

Fluorescence Polarization Assays. Binding affinities of PDZ domains for fluorescein-labeled peptides were determined using a 2103 Multilabel Reader (PerkinElmer). Briefly, fluorescein-labeled peptides were diluted to a final concentration of 2-5 nM and incubated with increasing concentrations of hexaHis-tagged-PDZ domains (0-100 µM; 12 datapoints), using duplicate protein titrations in 384-well Corning plates. After mixing on a shaking platform for 2 min at 500 rpm and centrifuging for 2 min at  $1,000 \times g$ , the fluorescence polarization signals from the wells were measured. The data were analyzed using the Graphpad Prism software and  $K_{\rm D}$ values were determined by curve fitting the data to a single bindingsite model.

Cloning. Full-length Scribble, mitogen-activated kinase 12 (MK12), guanylate cyclase soluble subunit  $\alpha$ -2 (GCAY2) constructs were generated by Gateway cloning (Invitrogen) from entry clones in pDONR223 and shuttled into pcDNA5 FRT/TO with either an N terminus GFP or 3xFlag tag. CTNB1 was PCR-amplified and cloned into pCMV2B (Stratagene) that contains a Flag-tag sequence at the N terminus. PKP4 was PCR-amplified and cloned into the Creator vector 3xFlag N terminus expression vector using the Creator recombination system (8).

Cell Line. HEK293T cells were maintained in DMEM (ATCC) supplemented with 10% FBS and 1% pen/strep/glutamine, and the appropriate selection antibiotics when required.

Coimmunoprecipitations. HEK293T cells were cotransfected with GFP-Scribble and Flag-tagged constructs (described above). Cells were lysed 48 h after transfections with radioimmune precipitation assay buffer [50 mM Tris HCl, pH 7.4, 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 10 mM Na<sub>3</sub>VO<sub>4</sub>, 10 mM sodium pyrophosphate, 25 mM NaF, 1x protease inhibitor mixture (Sigma)] for 30 min at 4 °C and and coimmunoprecipited with a GFP specific antibody (Abcam), as described previously (9). The resulting immunocomplexes and whole-cell lysates were analyzed by Western blot using the antibodies indicated in Fig. 4B. Protein samples were separated on a NuPage Bis-Tris 10% SDS/PAGE gel (Invitrogen) and transferred to nitrocellulose or PVDF membranes. Transferred samples were immunoblotted with primary anti-Flag antibodies, followed by incubation with horseradish peroxidase-conjugated goat antirabbit secondary antibodies (Santa Cruz Biotechnology) and detected using enhanced chemiluminescence (GE Healthcare).

Immunofluorescence. HEK293T cells were cotransfected with GFP-Scribble and Flag-tagged target constructs. Forty-eight hours after transfection, cells were fixed with 100% methanol for 20 min. Anti-Flag antibodies (1:400 Sigma) were incubated at room temperature for 1 h. Z-stack images were captured at room temperature by the Leica DMI6000B confocal microscope with a Leica 20×/0.40 NA objective lens and a Hamamatsu EM-CCD digital camera (C9100-13), and imported into Volocity software. The imaging medium was PBS.

Supplemental Network Analysis. We created a protein-protein interaction network of the four PDZ-containing proteins with their 78 putative binding using Cytoscape (10). The disk large homolog 1 (DLG1) part of the network contains previously known interactions with anion transporters, potassium channels, and G protein-coupled receptors. Consistent with the role of DLG1 in neuronal signaling, there are also known interactions with proteins involved in neuronal transmission, such as the motor protein KIF1 $\beta$  (11) and the microtubule-binding protein CRIPT (12). Among the new ligands we predict for DLG1, we highlight the Ras association domain-containing protein 6 (RASSF6), which interacts with the mammalian Ste20-like kinases (MST1/2), which are core kinases of the Hippo pathway (13). The suggested interaction between DLG1 and RASSF6 may add to the growing list of links between the cell polarity proteins and the Hippo signaling pathway (14). In addition, our predicted interactions between DLG1 and the E3 ubiquitin ligases DCNL1, RNF12, and MARCH3 may suggest unexplored connections between the ubiquitin system and the DLGs. Overall, the putative ligands appear relevant to the functions of DLG1.

Consistent with previous studies and roles in cell polarity and adhesion, the network of the LAP proteins Densin-180, Erbin, and Scribble contains interactions with the catenin family members PKP4, δ-catenin, and ARVCF, proteins that are found at the adherens junctions where they are involved in cell polarity and motility, but are also found in the nucleus where they are involved in transcriptional regulation (15-17). We also confirmed the interaction between Scribble and ARGH7, which is involved in cell migration, attachment, and cell spreading (18), and suggest novel interactions with a set of organic anion transporters and potassium channels as well as some nuclear proteins involved in transcriptional regulation, such as ATD2B. Scribble is not known to localize to the nucleus but it cannot be excluded that the proteins interact under specific circumstances. For example, ATD2B has been detected in the cytoplasm in some cancer cells (19). Under normal conditions, however, it is possible that the ATD2B C terminus is recognized by other class I PDZ proteins, such as NHERF2, that shuttle between the cytoplasm and the nucleus (20).

- 1. Tonikian R, et al. (2008) A specificity map for the PDZ domain family. PLoS Biol 6(9): e239.
- 2. Rajan S, Sidhu SS (2012) Simplified synthetic antibody libraries. Methods Enzymol 502: 3-23.
- 3. McLaughlin ME, Sidhu SS (2013) Engineering and analysis of peptide-recognition domain specificities by phage display and deep sequencing. Methods Enzymol 523:
- 4. Quail MA, et al. (2008) A large genome center's improvements to the Illumina sequencing system. Nat Methods 5(12):1005-1010.
- 5. Kim T, et al. (2012) MUSI: An integrated system for identifying multiple specificity from very large peptide or nucleic acid data sets. Nucleic Acids Res 40(6):e47.
- 6. Monera OD, Sereda TJ, Zhou NE, Kay CM, Hodges RS (1995) Relationship of sidechain hydrophobicity and alpha-helical propensity on the stability of the single-stranded amphipathic alpha-helix. J Pept Sci 1(5):319-329.

- Lam HY, et al. (2010) MOTIPS: Automated motif analysis for predicting targets of modular protein domains. BMC Bioinformatics 11:243.
- Colwill K, et al. (2006) Modification of the Creator recombination system for proteomics applications—Improved expression by addition of splice sites. BMC Biotechnol 6:13.
- Mak AB, et al. (2010) A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency. *Mol Cell Proteomics* 9(5):811–823.
- Cline MS, et al. (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2(10):2366–2382.
- Mok H, et al. (2002) Association of the kinesin superfamily motor protein KIF1Balpha with postsynaptic density-95 (PSD-95), synapse-associated protein-97, and synaptic scaffolding molecule PSD-95/discs large/zona occludens-1 proteins. J Neurosci 22(13): 5253–5258.
- Cai C, Coleman SK, Niemi K, Keinänen K (2002) Selective binding of synapse-associated protein 97 to GluR-A alpha-amino-5-hydroxy-3-methyl-4-isoxazole propionate receptor subunit is determined by a novel sequence motif. J Biol Chem 277(35):31484–31490.

- Ikeda M, et al. (2009) Hippo pathway-dependent and -independent roles of RASSF6. Sci Signal 2(90):ra59.
- Boggiano JC, Fehon RG (2012) Growth control by committee: Intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling. Dev Cell 22(4):695–702.
- Laura RP, et al. (2002) The Erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of delta-catenin and ARVCF. J Biol Chem 277(15):12906–12914.
- Izawa I, et al. (2002) ERBIN associates with p0071, an armadillo protein, at cell-cell junctions of epithelial cells. Genes Cells 7(5):475–485.
- Zhang Y, et al. (2006) Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families. J Biol Chem 281(31):22299–22311.
- Audebert S, et al. (2004) Mammalian Scribble forms a tight complex with the betaPIX exchange factor. Curr Biol 14(11):987–995.
- Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP (2010) ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. *Dev Growth Differ* 52(9):747–755.
- Thevenet L, et al. (2005) NHERF2/SIP-1 interacts with mouse SRY via a different mechanism than human SRY. J Biol Chem 280(46):38625–38630.



Fig. S1. Overview of the viral library design based on host organism.



**Fig. S2.** Comparison between logos derived from ProP-PD and conventional peptide-phage display. On the left logos as derived from the Tonikian et al. (1) study using a combinatorial peptide-phage library, on the right logos derived from ProP-PD experiments. "Accumulated hydrophobicity ratio ProP-PD/Tonikian" gives the ratio of the accumulated and normalized hydrophobicity (see *Methods*). Values smaller than one indicate a more hydrophobic PWM for the data obtained from the conventional phage library.



Fig. S3. Correlation between affinities and sequencing counts for Scribble PDZ3. Semilog scale plot of the sequencing counts versus affinities with a linear fit. The two red squares indicate outliers (the DNM1L peptide, to the left) and the GSPDSWV peptide (to the right).



Fig. S4. Colocalization of Scribble with CTNB1 and DNM1L, respectively. (A) Colocalization of GFP-tagged full-length Scribble with Flag-tagged CTNB1 and DNM1L 48 h after cotransfection in HEK293T cells (confocal micrographs). (Scale bars, 15 μm.)



**Fig. S5.** Comprehensive network of identified interactions. The bait proteins (Densin-180 PDZ; Erbin PDZ; Scribble PDZ1, PDZ2, and PDZ3; and DLG1 PDZ1, PDZ2, and PDZ3) are indicated by gray diamonds. Ligands identified by ProP-PD experiments are indicated by circles, in which colors indicate their biological processes. The width of the connecting lines reflect the frequency of a ligand in the sequencing data, with the ligands divided into three categories: high  $[log_{10}(counts) > 3]$ , medium  $[3 > log_{10}(counts) > 2]$ , and low  $[log_{10}(counts) < 2]$ . The color of the connecting branches indicates if the interactions are novel (gray), known (green), or here validated (yellow). The network was designed using the program Cytoscape (10).



**Fig. S6.** Frequency of mutated peptides versus designed parental peptides after the fifth round of selection. The comparison between the amount of sequences with point mutations (*x* axis) to the frequency of their parental sequences ("Frequency parental peptides," *y* axis, log-scale) illustrates that the more selected a wild-type peptide is, the more mutants of it will accumulate during the phage propagation.

♥ <

## Table S1. Comprehensive list of selected targets for each domain with literature references when applicable

Scribble PD21     RFLETKL     67.51     47.351     112.665     87.2271,HUMAN     Audebert et al. (1)     15.227     2     3       Scribble PD21     MMETT     286     5     2.51     AHRG,HUMAN     Audebert et al. (1)     15.22     4.61     15.52     4.61     15.52     4.61     15.52     4.61     15.52     4.61     15.52     4.61     15.52     4.61     15.52     4.61     15.52     4.61     14.469     15.52     4.61     14.469     12.100	Protein	Peptide	Library A	Library B	Total	Uniprot	Source	PMID	Rank ProP-PD	Rank Tonikian
Scribble PD21     MVDETNL     3,000     1,552     4,561     AHKG, HUMAN     1     155       Scribble PD21     TSRETDL     9     1     10     KCMAS, HUMAN     1     15       Scribble PD21     TSRETDL     9     1     10     KCMAS, HUMAN     1     12,927       Scribble PD21     REESTM     0     1     10     KCMAS, HUMAN     1     1,2297       Scribble PD22     ROSPSWV     0     6     168     618     618     614     NARES, HUMAN     2     1     2     168       Scribble PD22     VORTIVL     75     70     164     NARES, HUMAN     4     4     6     144,683       Scribble PD23     VORTIVL     75     70     144     NARES, HUMAN     4     146     146,833       Scribble PD23     VORTIVL     83     144,428     NYRES, HUMAN     4     146       Scribble PD23     REETH     2.21     12,738     2.04 CD2     1412     2.04 CD2     2.04 CD2     2.04 CD2     <	Scribble PDZ1	RFLETKL	67,514	45,351	112,865	B7Z2Y1_HUMAN			1	4
Scribble PD21     IMFETEL     286     5     291     AHKG, HUMAN     Zhang et al. (2)     16737968     4     156       Scribble PD21     REESTM     0     8     8     VMCL, HUMAN     2     12,927       Scribble PD21     REFHUW     0     6     641,4691     2,100       Scribble PD22     SPDSWV     0     618     PKH_HUMAN     2     12,6       Scribble PD22     RETRIL     35     41     76     BYTMAN     4     4       Scribble PD22     RETRIL     35     31     3     5     5     3     3     3       Scribble PD23     RETRIL     30,601     27,064     SARAG/T, HUMAN     Audebert et al. (1)     15182672     2     32       Scribble PD23     RETRIL     12,81     17,29     AUDE HUMAN     44     1,42     33       Scribble PD23     RETRIL     12     7,318     7,320     ATD2 HUMAN     49     1,22       Scribble PD23     RETRIL     12     7,320     ATD2 HUMAN <td>Scribble PDZ1</td> <td>AWDETNL</td> <td>3,009</td> <td>1,552</td> <td>4,561</td> <td>ARHG7_HUMAN</td> <td>Audebert et al. (1)</td> <td>15182672</td> <td>2</td> <td>25</td>	Scribble PDZ1	AWDETNL	3,009	1,552	4,561	ARHG7_HUMAN	Audebert et al. (1)	15182672	2	25
Scribble PD21     TSRETDL     9     1     10     KCMAS, HUMAN     Zhang et al. (2)     16737968     4     186       Scribble PD21     REFHLW     7     0     7     DMML1, HUMAN     1     2,100       Scribble PD22     SGRSWV     0     618	Scribble PDZ1	HMFETFL	286	5	291	ARHG8_HUMAN			3	15
Scribble PD21     RGEESTM     0     8     8     VMCC_HUMAN     5     12,927       Scribble PD22     GSPDSWV     0     618     PKR4_HUMAN     1     2,100       Scribble PD22     GSPDSWV     0     618     PKR4_HUMAN     2     125       Scribble PD22     GSPDSWV     6     12     38     ARGE_THUMAN     4     46       Scribble PD22     KPLETKL     23     38     ARGE_THUMAN     4     46       Scribble PD22     KPUSTW     61     7.57     7.67     7.27     7.52     5.23       Scribble PD23     MVDTML     82.801     7.79     80     7.597     7.67     7.67     7.57     7.52     7.28     7.75	Scribble PDZ1	TSRETDL	9	1	10	KCNA5_HUMAN	Zhang et al. (2)	16737968	4	186
Scribble PD21     IRETHUW     7     0     7     DMML1_HUMAN     1     2,100       Scribble PD22     SPRSWU     6     16     RVPE_JHUMAN     2     126       Scribble PD22     AVMDETN     29     29     58     AHRG7_HUMAN     3     3       Scribble PD22     AVMDETN     29     29     58     AHRG7_HUMAN     4     46       Scribble PD22     AVMDETN     20     1     21     ZSWM1_HUMAN     4     46       Scribble PD22     AVMDETN     30,601     27,005     57,697     AHRG7_HUMAN     4     14       Scribble PD23     HWETTN     2     7,138     7,320     ADD23_HUMAN     4     14       Scribble PD23     HWETTN     7     1,271     30,000     P2271_HUMAN     5     166       Scribble PD23     HWETTN     7     1,272     ADADD HUMAN     4     14       Scribble PD23     FRETNL     7     10     5     10     12     2     7       Scribb	Scribble PDZ1	RGEESTM	0	8	8	VWCE_HUMAN			5	12,927
Scribble PD22     GSPDSWV     0     618     FRM, HUMAN     1     2,100       Scribble PD22     RFLETKL     35     1     16     NPE2, HUMAN     2     126       Scribble PD22     RFLETKL     35     4     1     6     NPE2, HUMAN     3     3       Scribble PD22     ARPDSWV     6     32     38     TIND2, HUMAN     4     46       Scribble PD23     VQHITWL     83,844     17,68     101,482     NPE2, HUMAN     4     1     55       Scribble PD23     RUETL     1,228     17,719     30,000     322,271, HUMAN     4     14       Scribble PD23     RUETL     7,318     73,20     ATD2, HUMAN     4     14       Scribble PD23     RUETL     7,318     73,20     ATD2, HUMAN     4     14       Scribble PD23     RUETL     7,738     73,20     ATD2, HUMAN     5     112       Scribble PD23     RUETL     1,823     GTA2, HUMAN     1     1     1,23     3     3 <t< td=""><td>Scribble PDZ1</td><td>IRETHLW</td><td>7</td><td>0</td><td>7</td><td>DNML1_HUMAN</td><td></td><td></td><td>6</td><td>41,469</td></t<>	Scribble PDZ1	IRETHLW	7	0	7	DNML1_HUMAN			6	41,469
Scribble PD22     VQHITWL     76     70     146     NPR2_HUMAN     2     126       Scribble PD22     AWDETNL     29     29     58     AHRG7_HUMAN     Audebert et al. (1)     15182672     4     46       Scribble PD22     AVDETNL     29     29     58     AHRG7_HUMAN     Audebert et al. (1)     15182672     4     46       Scribble PD22     FVEQVQL     20     1     21     ZSWM1_HUMAN     Audebert et al. (1)     15182672     2     322       Scribble PD23     FVEQVQL     20     7.13     7.320     ADD24     HUMAN     4     14       Scribble PD23     FVETVL     2     7.18     7.320     ADD2     HUMAN     5     112       Scribble PD23     FVETVL     1     1,19     1,14     MUN1_HUMAN     7     7     77       Scribble PD23     FVETVL     1     7.25     GCYA2_HUMAN     7     17     7       Scribble PD23     FVETSU     1     2.25     GCYA2_HUMAN     11     1.2	Scribble PDZ2	GSPDSWV	0	618	618	PKP4_HUMAN			1	2,100
Scribble PD22     RFLEFKL     35     41     76     B722Y1_HUMAN     Audebert et al. (1)     15182672     4     46       Scribble PD22     SAPDSTW     6     32     38     CTND2_HUMAN     Audebert et al. (1)     15182672     4     46       Scribble PD23     VORHTWL     83,844     17,638     101,482     NNRE2_HUMAN     1     153       Scribble PD23     NUETNL     30,000     27,305     7,817     11     11     15182672     2     322       Scribble PD23     NLETL     1,719     30,000     8722Y1_HUMAN     Audebert et al. (1)     15182672     322     322       Scribble PD23     NLETL     7,318     7,320     AT22 HUMAN     5     312       Scribble PD23     NLETL     1,319     DMILL_HUMAN     7     7     77       Scribble PD23     NLETL     1,328     AP22_HUMAN     10     1     1       Scribble PD23     NLETL     1,328     AD42_Z HUMAN     10     1     1     1,328       Scribble	Scribble PDZ2	VQRHTWL	76	70	146	NXPE2_HUMAN			2	126
Scribble PD22     AWDEF NIL     29     29     58     ARHG7_HUMAN     Audebert et al. (1)     15182672     4     46       Scribble PD22     PYEQVOL     20     1     21     ZXMM1_HUMAN     6     11,669       Scribble PD23     AWDETNL     30,601     Z7,096     57,697     ARHG7_HUMAN     Audebert et al. (1)     15182672     2     322       Scribble PD23     MMETTI     30,601     Z7,096     57,697     ARHG7_HUMAN     Audebert et al. (1)     15182672     2     322       Scribble PD23     MMETTI     2     7,318     7,320     ATD28_HUMAN     4     44     14       Scribble PD23     IRETHU     1     1,728     ADATD4     10     11     128       Scribble PD23     IRETHS     1     252     253     GCYA2_HUMAN     10     1     123       Scribble PD23     IRETHS     1     252     253     GCYA2_HUMAN     10     1     123       Scribble PD23     IRETAL     1     254     SCMA2_HUMAN	Scribble PDZ2	RFLETKL	35	41	76	B7Z2Y1_HUMAN			3	3
Scribble PD22     Serbols PD22     Serbols PD22     Serbols PD23     Serbols PD33	Scribble PDZ2	AWDETNL	29	29	58	ARHG7_HUMAN	Audebert et al. (1)	15182672	4	46
Scribble PD22     PYEQVOL     20     1     21     25XMIN_HUMAN     6     14,689       Scribble PD23     AWDETNL     30,601     Z/096     S7,697     AHRG7_HUMAN     Audebert et al. (1)     151826/72     2     322       Scribble PD23     MHETFL     12     7,318     7,320     AHRG7_HUMAN     4     14       Scribble PD23     IRTHLW     1     1,193     1,278     ADAID HUMAN     5     112       Scribble PD23     IRTHLW     1     1,193     1,278     ADAID HUMAN     6     36,666       Scribble PD23     IRTHLW     1     1,114     MR12,HUMAN     9     9       Scribble PD23     RRETSL     1     252     253     GCYA2,HUMAN     10     1     1     1230       Scribble PD23     RRETSL     1     252     253     GCYA2,HUMAN     12     16737968     14     228       Scribble PD23     RNETSL     1     215     KMEH     10     13     3     23     24     24     <	Scribble PDZ2	ASPDSWV	6	32	38	CTND2_HUMAN			5	523
Scribble PD23     VQRHTWL     83,844     17,638     101,632     NXPEZ     JUNAN     1     55       Scribble PD23     RFLETKL     12,281     17,719     30,000     872271,HUMAN     3     13       Scribble PD23     NIRETDI     784     494     1,729     ADATD_HUMAN     5     112       Scribble PD23     NIRETDI     784     494     1,739     ADATD_HUMAN     6     36,666       Scribble PD23     POKETOL     725     302     0     302     RBT_LHUMAN     9     99       Scribble PD23     DRKETSI     302     0     302     RBT_LHUMAN     9     99       Scribble PD23     DRKTSI     1     242     253     GCAVA_LHUMAN     10     1     1       Scribble PD23     DRKTSI     1     242     254     MARA_LHUMAN     12     342       Scribble PD23     DRKTSI     1     242     255     GCRESTI     12     215     236       Scribble PD23     DRKTSI     30     3	Scribble PDZ2	PYEQVQL	20	1	21	ZSWM1_HUMAN			6	14,689
Scribble PD23     AWDE INU     30,001     27,095     57,697     ARHG, JUMAN     Audebert et al. (1)     1518,26/2     2     222       Scribble PD23     IMFETFL     2     7,318     7,320     ATD28 HUMAN     4     14       Scribble PD23     IRETHU     1     1,193     1,194     DMML, HUMAN     6     36,666       Scribble PD23     IRETTU     1     1,193     1,194     DMML, HUMAN     6     36,666       Scribble PD23     IRETTSL     1     222     Z53     GCYA2, HUMAN     10     1       Scribble PD23     IRETTSL     1     222     Z53     GCYA2, HUMAN     12     342       Scribble PD23     IRETAL     1     2215     MREA HUMAN     12     32       Scribble PD23     IRETAL     1     2215     MREA HUMAN     13     22       Scribble PD23     IRETAL     103     145     236     GCYA2, HUMAN     16     39,666       Scribble PD23     IRETAL     104     114     IRETAL     10	Scribble PDZ3	VQRHTWL	83,844	17,638	101,482	NXPE2 _HUMAN		45400670	1	55
Scribble PD23     NHETRL     12,231     17,719     30,000     87,227     114       Scribble PD23     NIRETD     784     494     1,728     ADATD_HUMAN     5     112       Scribble PD23     NIRETD     784     494     1,728     ADATD_HUMAN     5     112       Scribble PD23     SKETPL     782     302     707     501     101     1       Scribble PD23     DRKTSI     302     0     302     RBP_HUMAN     9     99       Scribble PD23     REKTSI     1     242     253     GCXA_2 HUMAN     10     1       Scribble PD23     REKTSI     1     242     215     MEPA_HUMAN     12     322       Scribble PD23     STEFTSI     1     242     215     MEPA_HUMAN     11     1.320       Scribble PD23     STEFTSI     10     11     111     IRK J_HUMAN     Scribble PD23     SCRIbBP23     SCRIbBP23     SCRIbBP23     SCRIBBP23     SCRIBBP23     SCRIBBP23     SCRIBBP23     SCRIBBP23     SCRIBBP23	Scribble PDZ3	AWDEINL	30,601	27,096	57,697	ARHG/_HUMAN	Audebert et al. (1)	15182672	2	322
Scribble PD23     HMFETIL     2     7,318     7,320     A1228     AUARAN     4     14       Scribble PD23     IRETHU     1     1,193     1,194     DMML_HUMAN     6     36,666       Scribble PD23     IRETHU     1     1,193     1,141     MK12L,HUMAN     6     36,666       Scribble PD23     POKETG     775     0     775     SOICL_HUMAN     8     77       Scribble PD23     FIRETSL     1     222     223     GCYA2,HUMAN     10     1       Scribble PD23     FIRETSM     91     145     236     GCXA2,HUMAN     12     342       Scribble PD23     FIRETAN     91     145     236     GCXA2,HUMAN     12     342       Scribble PD23     STEFDL     174     0     174     GTM2     16737968     14     28       Scribble PD23     STEFTDL     7     86     37     14     30,860       Scribble PD23     STEFTDL     7     86     37     39     39 <td< td=""><td>Scribble PDZ3</td><td>RFLEIKL</td><td>12,281</td><td>1/,/19</td><td>30,000</td><td>B/Z2Y1_HUMAN</td><td></td><td></td><td>3</td><td>13</td></td<>	Scribble PDZ3	RFLEIKL	12,281	1/,/19	30,000	B/Z2Y1_HUMAN			3	13
Scribble PD23     NIRE IDI     784     494     1,22     ADAID_HUMAN     5     112       Scribble PD23     VSKTPL     782     359     1,141     MK12_HUMAN     7     179       Scribble PD23     PKRTSI     302     0     302     RBP1_HUMAN     9     99       Scribble PD23     RKTSI     302     0     302     RBP1_HUMAN     9     99       Scribble PD23     RKTSI     1     225     CSCA2_HUMAN     10     1     1,230       Scribble PD23     RWETSI     1     248     249     ADA22_HUMAN     13     2     323       Scribble PD23     RKETHL     203     12     215     MRP4_HUMAN     Xhang et al. (2)     16737968     16     3.906       Scribble PD23     SKETHL     9     9     9     87     MET_HUMAN     Xhang et al. (2)     16737968     17     5       Scribble PD23     SKETHL     9     8     MCAS_HUMAN     Xhang et al. (2)     16737968     17     5     3.06	Scribble PDZ3	HMFEIFL	2	/,318	7,320	ATD2B_HUMAN			4	14
Scribble PD23     INETHUW     1     1,193     1,194     DNMIL_HUMAN     6     36,666       Scribble PD23     PKKETQL     775     0     775     501C1,HUMAN     7     779       Scribble PD23     FIRETSL     1     252     253     GCYA2,HUMAN     9     99       Scribble PD23     FIRETSL     1     248     249     ADA2     11     1,233       Scribble PD23     FIRETSL     1     248     249     ADA2     11     1,233       Scribble PD23     FIRETSL     93     12     ISMEHA     13     2       Scribble PD23     SKRTDL     174     0     174     CTNB1.HUMAN     Xhang et al. (2)     16737968     14     228       Scribble PD23     SKRTDL     7     86     39     KCNA5,HUMAN     Xhang et al. (2)     16737968     19     877       Scribble PD23     SKRTTAL     0     39     39     DKL2,HUMAN     Xhang et al. (2)     16737968     19     877       Scribble PD23	Scribble PDZ3	NLRETDI	784	494	1,278	ADA1D_HUMAN			5	112
Scribble PD23     SKRETPL     7/8     353     1,141     MR12_HUMAN     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7     5     7	Scribble PDZ3	IRETHLW	1	1,193	1,194	DNM1L_HUMAN			6	36,666
Scribble PD23     PKRETSL     1     252     253     GCYA2, HUMAN     9     9       Scribble PD23     FRETSL     1     252     253     GCYA2, HUMAN     10     1       Scribble PD23     FRETSL     1     254     249     ADA22, HUMAN     12     342       Scribble PD23     TIFETAL     203     12     215     MRP4, HUMAN     12     342       Scribble PD23     TIFETAL     203     14     CTNB1, HUMAN     Mang et al. (2)     16737968     14     228       Scribble PD23     GEKETHL     94     76     170     S6A12, HUMAN     Geller et al. (3)     2152870     15     23       Scribble PD23     GEKETHL     9     9     87 KETML     18     30.660       Scribble PD23     SGRETAL     0     39     43     RKR4, HUMAN     12     16737968     19     87       Scribble PD23     SGRETAL     0     39     13     ALREA, HUMAN     21     26     26     21     26     26	Scribble PDZ3	VSKETPL	/82	359	1,141	MK12_HUMAN			/	179
Scribble PD23     EIRETSL     1     252     253     CYA2_HUMAN     1     1     1       Scribble PD23     RLWETSI     1     248     249     ADA22_HUMAN     11     1,1,230       Scribble PD23     TIFETAL     203     12     215     MRPA_HUMAN     13     2       Scribble PD23     SWETSL     10     174     00     174     CTBL_HUMAN     16     3,906       Scribble PD23     SWETSL     10     111     111     IK12_HUMAN     56     3,906       Scribble PD23     SKETEHL     94     76     170     S6A12_HUMAN     Xhang et al. (2)     16737968     17     5       Scribble PD23     SKETENL     7     86     93     KCMAS_HUMAN     Xhang et al. (2)     16737968     18     3,080       Scribble PD23     SVESDE     55     0     55     ACTN1,2,3,4_HUMAN     Xhang et al. (2)     16737968     19     877       Scribble PD23     SVESDE     3     26     25     S1540     17 <t< td=""><td>Scribble PDZ3</td><td>PGKETQL</td><td>//5</td><td>0</td><td>//5</td><td>SO1C1_HUMAN</td><td></td><td></td><td>8</td><td>//</td></t<>	Scribble PDZ3	PGKETQL	//5	0	//5	SO1C1_HUMAN			8	//
Scribble PD23     FIKEISL     1     2.52     CCYA2_HUMAN     10     1       Scribble PD23     FIKETSM     91     145     2.25     GCYA2_HUMAN     12     342       Scribble PD23     TIFETAL     203     12     215     MRP4_HUMAN     12     342       Scribble PD23     SEKETHL     94     76     170     SGA12_HUMAN     16737968     14     228       Scribble PD23     SRESTDL     7     86     93     KCNA5_HUMAN     Khang et al. (2)     16737968     17     5       Scribble PD23     SRESTDL     7     86     93     KCNA5_HUMAN     Xhang et al. (2)     16737968     19     377       Scribble PD23     VRESDL     5     0     85     ACTN12_3.4_HUMAN     Xhang et al. (2)     16737968     19     377       Scribble PD23     VRESDL     2     3     21     268     29     14     14K4_HUMAN     22     104       Scribble PD23     VRESTAL     0     13     ANR50_HUMAN     23	Scribble PDZ3	DRKETSI	302	0	302	RBP1_HUMAN			9	99
Schlabe PD23     RVER13     I     248     249     AUA22_FUMAN     I     I     I, 230       Scribble PD23     TRETAL     203     12     215     MRP4_HUMAN     Xhang et al. (2)     16737968     14     228       Scribble PD23     GKERTHL     94     76     170     S6A12_HUMAN     Chang et al. (2)     16737968     15     23       Scribble PD23     SRESEL     100     11     111     IRK12_HUMAN     Geller et al. (3)     21525870     15     23       Scribble PD23     SRESEL     7     86     93     KCNA5_HUMAN     Xhang et al. (2)     16737968     17     5       Scribble PD23     SRESEAL     2     39     41     IRK12_HUMAN     Xhang et al. (2)     16737968     19     877       Scribble PD23     VEGEDL     5     0     54 ACTN12_JA_HUMAN     Xhang et al. (2)     16737968     19     877       Scribble PD23     VEGEDL     0     1     11     RARE_HUMAN     21     268       Scribble PD23	Scribble PDZ3	FLREISL	1	252	253	GCYA2_HUMAN			10	1
Scribble PD23     FirkLish     91     145     236     KLNB2_HUMAN     12     12     245       Scribble PD23     AWFDTDL     174     0     174     CTNB1     16737968     14     228       Scribble PD23     SGRETH     94     76     170     Scribble PD23     15228870     15     238       Scribble PD23     SFRESEI     100     11     111     IRK1_HUMAN     Khang et al. (2)     16737968     17     5       Scribble PD23     SFWETS     87     0     87     MET_HUMAN     Xhang et al. (2)     16737968     19     30,860       Scribble PD23     SFWETS     87     0     87     MET_HUMAN     20     42       Scribble PD23     VRKTAL     0     39     39     DLK2_HUMAN     21     268     22     104       Scribble PD23     SKETGL     3     26     29     S15A5_HUMAN     23     21     26       Scribble PD23     SKETGL     0     1     1     17     18	Scribble PDZ3	RLVVEISI	1	248	249	ADA22_HUMAN			11	1,230
Scribble PD23     SKRETPL     12     215     MKP4_HUMAN     Xhang et al. (2)     16737968     14     228       Scribble PD23     GKERTHL     94     76     170     SCAL     SCAL     SCAL     SCAL	Scribble PDZ3	PIREISM	91	145	236	KCNB2_HUMAN			12	342
Schnbie PD23     Schnbie PD23     Serk PD4     Schnbie PD3	Scribble PDZ3	TIFETAL	203	12	215	MRP4_HUMAN	) (I) (D)	46727060	13	2
Schnbie PD23     GREATER PLAS     GREATER PLAS     Construction     Construction<	Scribble PDZ3	AWFDIDL	1/4	0	174	CINB1_HUMAN	Xhang et al. (2)	16/3/968	14	228
Scribble PD23     TRKESH     100     11     111     IKR12_HUMAN     Xhang et al. (2)     16737968     17     5       Scribble PD23     STRKETS     87     0     87     MET_HUMAN     Xhang et al. (2)     16737968     19     877       Scribble PD23     VKRESAL     2     39     41     IRK1_HUMAN     Xhang et al. (2)     16737968     19     877       Scribble PD23     YKRETSAL     2     39     41     IRK4_HUMAN     20     422       Scribble PD23     YKKETPL     30     1     31     ANR50_HUMAN     223     21       Scribble PD23     GKRTGL     3     26     29     ISA5_HUMAN     223     21       Scribble PD23     GKRETGL     0     26     F189B_HUMAN     26     472       Scribble PD23     GKRETGL     0     14     14     ZN563_HUMAN     27     2,136       Scribble PD23     SKPETAL     0     15     STARS_HUMAN     27     2,136       Scribble PD23     MKYES1	Scribble PDZ3	GEKETHL	94	/6	170	S6A12_HUMAN	Gfeller et al. (3)	21525870	15	23
Scribble PD23   SKRIDL   7   86   93   RKNAS_HUMAN   Khang et al. (2)   16737968   17   5     Scribble PD23   LYGESDL   55   0   55   ACTN1,2,3,4_HUMAN   Xhang et al. (2)   16737968   19   877     Scribble PD23   YRRESAI   2   39   41   IRK4_HUMAN   Xhang et al. (2)   16737968   19   42     Scribble PD23   YRKETPL   30   1   31   ANRS0_HUMAN   22   104     Scribble PD23   DKKETPL   30   1   31   ANRS0_HUMAN   23   21     Scribble PD23   GSKETGL   0   26   29   515AS_HUMAN   23   21     Scribble PD23   GDLSTD   0   21   21   RFRTB_HUMAN   26   472     Scribble PD23   SGRETGL   0   15   15   STA8_HUMAN   28   48,049     Scribble PD23   SKPGTFL   0   14   14   20563_HUMAN   29   352     Scribble PD23   SKPGTFL   0   16   54,450   10   1172   11	Scribble PDZ3	YRRESEI	100	11	111	IRK12_HUMAN	) (I) (D)	46727060	16	3,906
Scribble PD23     Stribble PD23     Viet Stribble PD2	Scribble PDZ3	ISREIDL	/	86	93	KCNA5_HUMAN	Xhang et al. (2)	16/3/968	17	5
Scribble PD23   YRESAI   2   39   41   IRX4_HUMAN   20   42     Scribble PD23   YRKETAL   0   39   39   DLV2_HUMAN   21   268     Scribble PD23   YKKETPL   30   1   31   ANRS0_HUMAN   23   21     Scribble PD23   DLWETAL   3   26   25   S15A5_HUMAN   23   21     Scribble PD23   GRUETGL   0   26   26   189B_HUMAN   26   27   9794     Scribble PD23   GRUETGL   0   21   21   RPR1B_HUMAN   26   472     Scribble PD23   GRUETSTL   0   15   15   STAR8_HUMAN   29   352     Scribble PD23   SGRUETTL   0   10   10   S4A4_HUMAN   29   352     Scribble PD23   SGRUETTL   0   10   10   S4A4_HUMAN   30   577     Scribble PD23   SVGRUETL   0   7   ILVX1_HUMAN   112049   2   35     Scribble PD23   SVGVETL   0   71,560   PKP4_HUMAN   Lau	Scribble PDZ3	ASEVVETS	8/	0	8/		)/h a mar at a [ ( <b>2</b> )	10777000	18	30,860
Scribble PD23   PKKTEDAL   2   39   41   INKA_HOMAN   20   42     Scribble PD23   PKKETPL   30   1   31   ANR50_HUMAN   22   104     Scribble PD23   DLWETAL   3   26   29   S15A5_HUMAN   23   21     Scribble PD23   GSRETGL   0   26   F1898_HUMAN   23   21     Scribble PD23   GSRETGL   0   21   21   RPR1B_HUMAN   26   472     Scribble PD23   GAGETKL   0   15   STAR_HUMAN   26   472     Scribble PD23   THWRETI   0   14   14   ZN563_HUMAN   29   352     Scribble PD23   SKPGTFL   0   7   7   LNX1_HUMAN   30   377     Scribble PD23   SVPGTFL   0   7   7   LNX1_HUMAN   10   30   577     Scribble PD23   SVPGTFL   0   7   7   LNX1_HUMAN   Laura et al. (4)   1172919   2   35     Densin-180   ASPDSWV   Failed   5,450   PKP4_HUMAN	Scribble PDZ3		55	0	55	ACINI,2,3,4_HUMAN	Xhang et al. (2)	16/3/968	19	877
Scribble PD23   YKKETPL   30   1   31   ANRSD, HUMAN   22   104     Scribble PD23   UKETAL   3   26   29   S15A5, HUMAN   23   21     Scribble PD23   GSRETGL   0   26   26   F189B, HUMAN   24   58     Scribble PD23   GDLFSTD   0   21   17   18   TMG1, HUMAN   26   472     Scribble PD23   AGPETKL   0   15   15   STAR8, HUMAN   26   472     Scribble PD23   THSTTL   0   14   42   14   2NS63, HUMAN   29   352     Scribble PD23   GKTETTL   0   10   10   54A4, HUMAN   31   356     Scribble PD23   SWPGTFL   0   7   1 NT1, HUMAN   31   356     Densin-180   GSPDSWV   Failed   5,450   PK44, HUMAN   11   170     Densin-180   GSPDSWV   64,274   71,946   136,220   CTND2, HUMAN   Laura et al. (4)   11729199   2   35     Erbin   GPDSWV   0   17,	Scribble PDZ3	TRRESAL	2	39	41				20	42
Scribble PD23   DWETAL   30   1   31   ANRSO_HOMAN   22   104     Scribble PD23   GSRETGL   0   26   29   515AS_HUMAN   23   21     Scribble PD23   GSRETGL   0   21   21   RPR18_HUMAN   23   9794     Scribble PD23   AGPETKL   0   15   15   STAR8_HUMAN   26   472     Scribble PD23   AGPETKL   0   15   15   STAR8_HUMAN   27   2,136     Scribble PD23   KGTETTL   0   10   14   2056_HUMAN   29   352     Scribble PD23   MYKSSDI   0   8   8   NR2E1_HUMAN   30   577     Scribble PD23   MYKSSDI   0   8   8   NR2E1_HUMAN   30   577     Scribble PD23   SVPGTFL   0   7   LNX1_HUMAN   11   170     Densin-180   GSPDSWV   Failed   5,459   PKP4_HUMAN   Lzawa et al. (4)   11221434   1   2     Erbin   GSPDSWV   17,680   PKP4_HUMAN   Lawa et al. (5)   <	Scribble PDZ3		20	39	39				21	208
Scribble PD23   GNUVETAL   3   20   29   STAS_FUNMAN   23   21     Scribble PD23   GDLFSTD   0   21   21   RPR1B_HUMAN   26   472     Scribble PD23   AGPETKL   1   17   18   TMIG1_HUMAN   26   472     Scribble PD23   AGPETKL   0   15   STARB_HUMAN   27   2,136     Scribble PD23   THWRETI   0   14   14   ZN563_HUMAN   28   48,049     Scribble PD23   MYKSSDI   0   8   8   NR2E1_HUMAN   29   352     Scribble PD23   SWPGTL   0   7   T LNX1_HUMAN   30   577     Scribble PD23   SVPGTFL   0   7   T LNX1_HUMAN   112awa et al. (4)   11729199   2   35     Densin-180   ASPDSWV   Failed   5,450   PKP4_HUMAN   Lawa et al. (5)   11821434   1   2     Erbin   QPVDSWV   17,680   PKP4_HUMAN   Lawa et al. (6)   12047349   2   3     Erbin   QVDYDW   114   2   116	Scribble PDZ3	YKKEIPL	30	1	31	ANK50_HUMAN			22	104
Scribble PD23   GDL FD23   GDL FD24   GDR FGL   0   20   F189E_PUMAN   24   38     Scribble PD23   GDL FSTD   0   21   21   RFR1E_HUMAN   26   472     Scribble PD23   FMSETAL   1   17   18   TMIG1_HUMAN   26   472     Scribble PD23   KGPETKL   0   15   15   STAR8_HUMAN   27   2,136     Scribble PD23   KGTETTL   0   10   10   S44_HUMAN   29   352     Scribble PD23   KYKSDI   0   8   8   NR2E1_HUMAN   30   577     Scribble PD23   SVPSTFL   0   7   TLN1_HUMAN   30   356     Densin-180   GSPDSWV   Failed   5,450   PKP4_HUMAN   Laura et al. (4)   1172919   2   35     Erbin   GSPDSWV   Failed   17,680   PKP4_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   GSPDSWV   1,748   18,35   ARVC_HUMAN   Laura et al. (5)   11821434   3   4     Erbin	Scribble PDZ3		3	20	29	SISAS_HUIVIAN			23	21
Actinatione PD23   PISETAL   1   17   18   NRME_HOMAN   25   9,794     Scribble PD23   AGPETKL   0   15   15   STAR8_HUMAN   27   2,136     Scribble PD23   KGTETTL   0   14   14   ZN563_HUMAN   28   48,049     Scribble PD23   KGTETTL   0   10   10   StaR8_HUMAN   29   352     Scribble PD23   SKGTETTL   0   7   7   LNX1_HUMAN   30   577     Scribble PD23   SVPGTFL   0   7   7   LNX1_HUMAN   31   356     Densin-180   GSPDSWV   Failed   2,794   27,94   CTND2_HUMAN   Laura et al. (4)   11729199   2   35     Erbin   ASPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   GSPDSWV   0   17,680   PKP4_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   YDVTDV   114   2   116   GR87_HUMAN   Laura et al. (5)   11821434 <td>Scribble PDZ3</td> <td>GSREIGL</td> <td>0</td> <td>20</td> <td>20</td> <td></td> <td></td> <td></td> <td>24</td> <td>56 0 704</td>	Scribble PDZ3	GSREIGL	0	20	20				24	56 0 704
Scribble PD23   FINETAL   1   17   18   TMINE_HUMAN   20   4/2     Scribble PD23   THWRETI   0   14   14   ZN563_HUMAN   28   48,049     Scribble PD23   KGTETTL   0   10   10   SA4A_HUMAN   29   352     Scribble PD23   SKGTETL   0   10   SA4A_HUMAN   30   577     Scribble PD23   SWGTFL   0   7   7   INX1_HUMAN   31   356     Densin-180   GSPDSWV   Failed   5,450   5,450   PKP4_HUMAN   Izawa et al. (4)   11729199   2   35     Erbin   GSPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Izawa et al. (6)   12047349   2   3     Erbin   GSPDSWV   1,747   88   1,835   ARVC_HUMAN   Izawa et al. (5)   11821434   4   1,357     Erbin   VPDYDTDV   114   2   116   GRR2_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   VPDYDTDV   114   12   NS2_HUMAN   Laura et al. (5	Scribble PDZ3		1	17	21				25	5,754 470
Scribble PD23   HVRETI   0   10   10   SGRIDMEND   28   48,049     Scribble PD23   KKRETI   0   10   10   S4A4_HUMAN   29   352     Scribble PD23   SWPGTFL   0   7   7   LINX1_HUMAN   30   5777     Scribble PD23   SWPGTFL   0   7   7   LINX1_HUMAN   31   356     Densin-180   GSPDSWV   Failed   5,450   FKP4_HUMAN   Lawa et al. (4)   11729199   2   35     Erbin   GSPDSWV   Failed   2,794   2,794   CTND2_HUMAN   Lawa et al. (5)   11821434   1   2     Erbin   GSPDSWV   64,274   71,680   PKP4_HUMAN   Lawa et al. (5)   11821434   3   4     Erbin   QPVDSWV   1,747   88   1,835   ARVC_HUMAN   Lawa et al. (5)   11821434   3   4     Erbin   VQRHTWL   21   1   22   NPE2_HUMAN   Lawa et al. (5)   11821434   4   1,357     Erbin   VQRHTWL   11   71,40   BG422_HUMAN	Scribble PDZ3		0	17	10				20	472
Actingue PD23   NTMKLTI   0   14   14   24   20   46,049     Scribble PD23   MYKSSDI   0   8   8   NR2E1_HUMAN   30   577     Scribble PD23   SWPGTFL   0   7   7   LNX1_HUMAN   31   356     Densin-180   GSPDSWV   Failed   2,794   2,794   CTND2_HUMAN   1   170     Densin-180   ASPDSWV   Failed   2,794   2,794   CTND2_HUMAN   Laura et al. (4)   11729199   2   35     Erbin   ASPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   GSPDSWV   0   17,680   17,680   PKP4_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   VQPNDSWV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   VQPNTVL   21   1   22   NXPE2_HUMAN   Laura et al. (5)   11821434   3   4     DLG1 PD21   RKETKL   569	Scribble PDZ3		0	1/	1/				27	18 0/0
Actioner PD23   NKRLTTL   0   10   577     Scribble PD23   SWPGTFL   0   7   7   LNX1_HUMAN   11   10   11   170     Densin-180   GSPDSWV   Failed   2,794   CTND2_HUMAN   Laura et al. (4)   11729199   2   35     Erbin   ASPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Laura et al. (5)   11821434   1   2   3     Erbin   QPVDSWV   1,747   88   1,835   ARVC_HUMAN   Laura et al. (5)   11821434   3   4   1,357     Erbin   YDYDV   114   2   116   GPR3_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YDYDV   114   2   116   GPR3_HUMAN   Laura et al. (5)   11821434   3   4     DL	Scribble PDZ3	KGTETTI	0	14	14				20	40,049
Densine FD23   SWPGTFL   0   7   7   LIX1_HUMAN   31   356     Densin-180   GSPDSWV   Failed   5,450   5,450   PKP4_HUMAN   1   170     Densin-180   ASPDSWV   Failed   2,794   2,794   CTND2_HUMAN   Lava et al. (4)   11729199   2   35     Erbin   ASPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   QSPDSWV   1,747   88   1,835   ARVC_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YPYDTDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YPYDTDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   VPYDTVV   114   2   173   GA212_HUMAN   Laura et al. (5)   11821434   3   4     DLG1 PD21   RMSVHWV   11   0   131   TBX15_HUMAN   1   721   1   721 </td <td>Scribble PDZ3</td> <td></td> <td>0</td> <td>8</td> <td>10</td> <td>NR2E1 HUMAN</td> <td></td> <td></td> <td>30</td> <td>577</td>	Scribble PDZ3		0	8	10	NR2E1 HUMAN			30	577
Densin-180   GSPDSWV   Failed   5,450   PKP4_HUMAN   1   170     Densin-180   ASPDSWV   Failed   2,794   2,794   CTND2_HUMAN   Laura et al. (4)   11729199   2   35     Erbin   ASPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   GSPDSWV   0   17,680   PKP4_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   GVDSWVV   1,747   88   1,835   ARVC_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YPDYDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQPTDV   114   5   19   GA2L2_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   VQRHTWL   21   1   22   RXPE2_HUMAN   Laura et al. (5)   11821434   3   4     DLG1 PDZ1   RFLETKL   569   77   646   B722Y1_HUMAN   Laura et al. (3)   21525870	Scribble PD73	SWPGTEI	0	7	7				31	356
Densin-180   ASPDSWV   Failed   2,794   CTND2_HUMAN   Izawa et al. (4)   11729199   2   35     Erbin   ASPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   GSPDSWV   0   17,680   17,680   PKP4_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   QPVDSWV   1,747   88   1,835   ARVC_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YPDYDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YPDYDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQRHTWL   21   1   22   NXF2_HUMAN   Laura et al. (5)   11821434   3   4     DLG1 PDZ1   RFLETKL   569   77   646   B722Y1_HUMAN   Laura et al. (3)   21525870   1   24     DLG1 PDZ2   RKETLV   58,320   29,164   87,484   CTR2_	Densin-180	GSPDSWV	Failed	, 5 450	, 5 450	PKP4 HUMAN			1	170
Brish no.   ASPDSWV   64,274   71,946   136,220   CTND2_HUMAN   Laura et al. (5)   11821434   1   2     Erbin   GSPDSWV   0   17,680   PKP4_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   QPVDSWV   1,747   88   1,835   ARVC_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YYDYTDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQDYTDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQDYTDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQPTDV   114   5   19   GA2L2_HUMAN   Laura et al. (5)   11821434   1   2   1,230     DLG1 PDZ1   RKETKL   569   77   646   B722Y1_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RKETRV   58,320   29,164   87,484	Densin-180	ASPDSWV	Failed	2 794	2 794	CTND2 HUMAN	Izawa et al. (4)	11729199	2	35
Erbin   GSPDSWV   0   17,680   PKP4_HUMAN   Izawa et al. (6)   12047349   2   3     Erbin   QPVDSWV   1,747   88   1,835   ARVC_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YYDYDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQDYTDV   114   2   116   GPR87_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQRHTWL   21   1   22   NXPE2_HUMAN   4   1,357     Erbin   VQRHTWL   21   1   22   NXPE2_HUMAN   6   44     Erbin   PEEESWV   14   5   19   GA2L2_HUMAN   6   46     DLG1 PDZ1   RKETKL   569   77   646   B7221_HUMAN   1   721     DLG1 PDZ2   LRKETRV   58,320   29,164   87,484   CLTR2_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RSISTDV   14,224   24,273   38,497	Frbin	ASPDSWV	64.274	71,946	136,220	CTND2_HUMAN	Laura et al. (5)	11821434	1	2
Erbin   OPVDSWV   1,747   747   748   1,835   ARVC_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YYDYTDV   114   2   116   GPR7_HUMAN   Laura et al. (5)   11821434   3   4     Erbin   YQRHTWL   21   1   22   NXPE2_HUMAN   5   44     Erbin   PEEESWV   14   5   19   GA2L2_HUMAN   6   46     DLG1 PDZ1   RFLETKL   569   77   646   B7Z2Y1_HUMAN   1   721     DLG1 PDZ1   QMSVHMV   131   0   131   TBX15_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   LKKETRV   58,320   29,164   87,484   CLTR2_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RKKETLV   21,909   11,998   33,907   ARHO8_HUMAN   Carr et al. (7)   19586902   3   3     DLG1 PDZ2   KRKETLV   21,909   11,120   KIF1B_HUMAN   Garr et al. (8)   12097473   5   13     DLG1 PD	Frbin	GSPDSWV	0.,_, 1	17,680	17,680	PKP4 HUMAN	Izawa et al. (6)	12047349	2	- 3
Erbin   YYDYTDV   114   2   116   GPR87_HUMAN   4   1,357     Erbin   VQRHTWL   21   1   22   NXPE2_HUMAN   5   44     Erbin   PEEESWV   14   5   19   GA2L2_HUMAN   6   46     DLG1 PDZ1   RFLETKL   569   77   646   B7Z2Y1_HUMAN   1   721     DLG1 PDZ1   QMSVHMV   131   0   131   TBX15_HUMAN   Geller et al. (3)   21525870   1   24     DLG1 PDZ2   LRKETRV   58,320   29,164   87,484   CLTR2_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RKETLV   21,909   11,998   33,907   ARHG8_HUMAN   Carr et al. (7)   19586902   3   3     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gare et al. (3)   21525870   4   1     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gare et al. (3)   21525870   4   1     DLG1 PDZ2   SKETVV   421 <td>Erbin</td> <td>OPVDSWV</td> <td>1.747</td> <td>88</td> <td>1.835</td> <td>ARVC HUMAN</td> <td>Laura et al. (5)</td> <td>11821434</td> <td>3</td> <td>4</td>	Erbin	OPVDSWV	1.747	88	1.835	ARVC HUMAN	Laura et al. (5)	11821434	3	4
Erbin   VQRHTWL   21   1   22   NXPE2_HUMAN   5   44     Erbin   PEEESWV   14   5   19   GA2L2_HUMAN   6   46     DLG1 PDZ1   RFLETKL   569   77   646   B722Y1_HUMAN   1   721     DLG1 PDZ1   QMSVHMV   131   0   131   TBX15_HUMAN   2   1,230     DLG1 PDZ2   LRKETRV   58,320   29,164   87,484   CLTR2_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RSISTDV   14,224   24,273   38,497   F163B_HUMAN   2   2   2   2     DLG1 PDZ2   KRKETLV   21,909   11,998   33,907   ARHG8_HUMAN   Carr et al. (7)   19586902   3   3     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   NSKETVV   421 <td>Erbin</td> <td>YYDYTDV</td> <td>, 114</td> <td>2</td> <td>116</td> <td>GPR87 HUMAN</td> <td></td> <td></td> <td>4</td> <td>1.357</td>	Erbin	YYDYTDV	, 114	2	116	GPR87 HUMAN			4	1.357
Erbin     PEEESWV     14     5     19     GA2L2_HUMAN     6     46       DLG1 PDZ1     RFLETKL     569     77     646     B7Z2Y1_HUMAN     1     721       DLG1 PDZ1     QMSVHMV     131     0     131     TBX15_HUMAN     2     1,230       DLG1 PDZ2     LRKETRV     58,320     29,164     87,484     CLTR2_HUMAN     Gfeller et al. (3)     21525870     1     24       DLG1 PDZ2     RSISTDV     14,224     24,273     38,497     F163B_HUMAN     2	Erbin	VORHTWL	21	1	22	NXPE2 HUMAN			5	44
DLG1 PDZ1   RFLETKL   569   77   646   B7Z2Y1_HUMAN   1   721     DLG1 PDZ1   QMSVHMV   131   0   131   TBX15_HUMAN   2   1,230     DLG1 PDZ2   LRKETRV   58,320   29,164   87,484   CLTR2_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RSISTDV   14,224   24,273   38,497   F163B_HUMAN   2   2   2     DLG1 PDZ2   RSISTDV   14,224   24,273   38,497   F163B_HUMAN   Carr et al. (7)   19586902   3   3     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (8)   12097473   5   13     DLG1 PDZ2   NSKETVV   421   279   700   MARH3_HUMAN   Yamamoto et al. (9)   15021905 </td <td>Erbin</td> <td>PEEESWV</td> <td>14</td> <td>5</td> <td>19</td> <td>GA2L2 HUMAN</td> <td></td> <td></td> <td>6</td> <td>46</td>	Erbin	PEEESWV	14	5	19	GA2L2 HUMAN			6	46
DLG1 PDZ1   QMSVHMV   131   0   131   TBX15_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   LRKETRV   58,320   29,164   87,484   CLTR2_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RSISTDV   14,224   24,273   38,497   F163B_HUMAN   2   2   2     DLG1 PDZ2   KRKETLV   21,909   11,998   33,907   ARHG8_HUMAN   Carr et al. (7)   19586902   3   3     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   AGRETTV   719   10,401   11,120   KIF1B_HUMAN   Mok et al. (8)   12097473   5   13     DLG1 PDZ2   NSKETVV   421   279   700   MARH3_HUMAN   Yamamoto et al. (9)   15021905   7   41     DLG1 PDZ2   RAISTDV   185   15	DLG1 PDZ1	RFLETKL	569	77	646	B7Z2Y1 HUMAN			1	721
DLG1 PDZ2   LRKETRV   58,320   29,164   87,484   CLTR2_HUMAN   Gfeller et al. (3)   21525870   1   24     DLG1 PDZ2   RSISTDV   14,224   24,273   38,497   F1638_HUMAN   2   2     DLG1 PDZ2   KRKETLV   21,909   11,998   33,907   ARHG8_HUMAN   Carr et al. (7)   19586902   3   3     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   SARSTDV   4,643   16,686   21,329   ANO9_HUMAN   Gfeller et al. (3)   21525870   4   1     DLG1 PDZ2   AGRETTV   719   10,401   11,120   KIF1B_HUMAN   Mok et al. (8)   12097473   5   13     DLG1 PDZ2   NSKETVV   421   279   700   MARH3_HUMAN   Yamamoto et al. (9)   15021905   7   41     DLG1 PDZ2   WKHETTV   483   90   573   GP125_HUMAN   Yamamoto et al. (9)   15021905   7   41     DLG1 PDZ2   RAISTDV   185   155 <t< td=""><td>DLG1 PDZ1</td><td>QMSVHMV</td><td>131</td><td>0</td><td>131</td><td>TBX15 HUMAN</td><td></td><td></td><td>2</td><td>1,230</td></t<>	DLG1 PDZ1	QMSVHMV	131	0	131	TBX15 HUMAN			2	1,230
DLG1 PDZ2     RSISTDV     14,224     24,273     38,497     F163B_HUMAN     Carr et al. (7)     19586902     3     3       DLG1 PDZ2     KRKETLV     21,909     11,998     33,907     ARHG8_HUMAN     Carr et al. (7)     19586902     3     3       DLG1 PDZ2     SARSTDV     4,643     16,686     21,329     ANO9_HUMAN     Gfeller et al. (3)     21525870     4     1       DLG1 PDZ2     SARSTDV     4,643     16,686     21,329     ANO9_HUMAN     Gfeller et al. (3)     21525870     4     1       DLG1 PDZ2     AGRETTV     719     10,401     11,120     KIF1B_HUMAN     Mok et al. (8)     12097473     5     13       DLG1 PDZ2     NSKETVV     421     279     700     MARH3_HUMAN     Mok et al. (8)     12097473     5     13       DLG1 PDZ2     WKHETTV     483     90     573     GP125_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     RAISTDV     185     155     340     F163A_HUMAN     Yamamoto et	DLG1 PDZ2	LRKETRV	58,320	29,164	87,484	CLTR2_HUMAN	Gfeller et al. (3)	21525870	1	24
DLG1 PDZ2     KRKETLV     21,909     11,998     33,907     ARHG2 HUMAN     Carr et al. (7)     19586902     3     3       DLG1 PDZ2     SARSTDV     4,643     16,686     21,329     ANO9_HUMAN     Gfeller et al. (3)     21525870     4     1       DLG1 PDZ2     AGRETTV     719     10,401     11,120     KIF1B_HUMAN     Mok et al. (8)     12097473     5     13       DLG1 PDZ2     NSKETVV     421     279     700     MARH3_HUMAN     Mok et al. (8)     12097473     5     13       DLG1 PDZ2     NSKETVV     421     279     700     MARH3_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     WKHETTV     483     90     573     GP125_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     RAISTDV     185     155     340     F163A_HUMAN     8     18       DLG1 PDZ2     WKNETTV     255     35     290     GP123_HUMAN     9     218       DLG1 PDZ2 <t< td=""><td>DLG1 PDZ2</td><td>RSISTDV</td><td>14,224</td><td>24,273</td><td>38,497</td><td>F163B_HUMAN</td><td></td><td></td><td>2</td><td>2</td></t<>	DLG1 PDZ2	RSISTDV	14,224	24,273	38,497	F163B_HUMAN			2	2
DLG1 PDZ2     SARSTDV     4,643     16,686     21,329     ANO9_HUMAN     Gfeller et al. (3)     21525870     4     1       DLG1 PDZ2     AGRETTV     719     10,401     11,120     KIF1B_HUMAN     Gfeller et al. (3)     21525870     4     1       DLG1 PDZ2     AGRETTV     719     10,401     11,120     KIF1B_HUMAN     Mok et al. (8)     12097473     5     13       DLG1 PDZ2     NSKETVV     421     279     700     MARH3_HUMAN     6     5       DLG1 PDZ2     WKHETTV     483     90     573     GP125_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     RAISTDV     185     155     340     F163A_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     WKNETTV     255     35     290     GP123_HUMAN     9     218       DLG1 PDZ2     GTKSTTV     0     269     269     DCNL1_HUMAN     10     43	DLG1 PDZ2	KRKETLV	21,909	11,998	33,907	ARHG8_HUMAN	Carr et al. (7)	19586902	3	3
DLG1 PDZ2     AGRETTV     719     10,401     11,120     KIF1B_HUMAN     Mok et al. (8)     12097473     5     13       DLG1 PDZ2     NSKETVV     421     279     700     MARH3_HUMAN     6     5       DLG1 PDZ2     WSKETVV     421     279     700     MARH3_HUMAN     6     5       DLG1 PDZ2     WKHETTV     483     90     573     GP125_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     RAISTDV     185     155     340     F163A_HUMAN     8     18       DLG1 PDZ2     WKNETTV     255     35     290     GP123_HUMAN     9     218       DLG1 PDZ2     GTKSTTV     0     269     269     DCNL1_HUMAN     10     43	DLG1 PDZ2	SARSTDV	4,643	16,686	21.329	ANO9 HUMAN	Gfeller et al. (3)	21525870	4	- 1
DLG1 PDZ2     NSKETVV     421     279     700     MARH3_HUMAN     6     5       DLG1 PDZ2     WKHETTV     483     90     573     GP125_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     RAISTDV     185     155     340     F163A_HUMAN     8     18       DLG1 PDZ2     WKNETTV     255     35     290     GP123_HUMAN     9     218       DLG1 PDZ2     GTKSTTV     0     269     269     DCNL1_HUMAN     10     43	DLG1 PDZ2	AGRETTV	719	10,401	11,120	KIF1B HUMAN	Mok et al. (8)	12097473	5	13
DLG1 PDZ2     WKHETTV     483     90     573     GP125_HUMAN     Yamamoto et al. (9)     15021905     7     41       DLG1 PDZ2     RAISTDV     185     155     340     F163A_HUMAN     8     18       DLG1 PDZ2     WKNETTV     255     35     290     GP123_HUMAN     9     218       DLG1 PDZ2     GTKSTTV     0     269     269     DCNL1_HUMAN     10     43	DLG1 PDZ2	NSKETVV	421	279	700	MARH3_HUMAN	.,		6	5
DLG1 PDZ2     RAISTDV     185     155     340     F163A_HUMAN     8     18       DLG1 PDZ2     WKNETTV     255     35     290     GP123_HUMAN     9     218       DLG1 PDZ2     GTKSTTV     0     269     269     DCNL1_HUMAN     10     43	DLG1 PDZ2	WKHETTV	483	90	573	GP125_HUMAN	Yamamoto et al. (9)	15021905	7	41
DLG1 PDZ2     WKNETTV     255     35     290     GP123_HUMAN     9     218       DLG1 PDZ2     GTKSTTV     0     269     269     DCNL1_HUMAN     10     43	DLG1 PDZ2	RAISTDV	185	155	340	F163A_HUMAN			8	18
DLG1 PDZ2 GTKSTTV 0 269 269 DCNL1_HUMAN 10 43	DLG1 PDZ2	WKNETTV	255	35	290	GP123_HUMAN			9	218
	DLG1 PDZ2	GTKSTTV	0	269	269	DCNL1_HUMAN			10	43

PNAS PNAS

### Table S1. Cont.

Protein	Peptide	Library A	Library B	Total	Uniprot	Source	PMID	Rank ProP-PD	Rank Tonikian
DLG1 PDZ2	RHRNTVV	42	147	189	ERBB4_HUMAN	Huang et al. (10)	12175853	11	12
DLG1 PDZ2	MTKDTLV	60	18	78	PL8L1_HUMAN			12	42
DLG1 PDZ2	QRTHTRV	73	5	78	ZSC30_HUMAN			13	372
DLG1 PDZ2	SGISTIV	27	33	60	IQEC1_HUMAN			14	29
DLG1 PDZ2	GSPDSWV	0	54	54	PKP4_HUMAN	Izawa et al. (4)	12047349	15	314
DLG1 PDZ2	WKSETTV	42	5	47	GP124_HUMAN	Yamamoto et al. (9)	15021905	16	148
DLG1 PDZ2	GNRESVV	0	45	45	RNF12_HUMAN			17	17
DLG1 PDZ2	GGRQSVV	0	38	38	PRR5_HUMAN			18	16
DLG1 PDZ2	SSIESDV	18	18	36	NMDE2_HUMAN	Inanobe et al. (11)	11997254	19	28
DLG1 PDZ2	RDRESIV	19	16	35	SCN5A_HUMAN	Petitprez et al. (12)	21164104	20	19
DLG1 PDZ2	PGKETQL	2	29	31	SO1C1_HUMAN			21	108
DLG1 PDZ2	KIKETTV	15	12	27	FRPD4_HUMAN	Lee et al. (13)	19118189	22	38
DLG1 PDZ2	IKTETTV	12	12	24	RASF6_HUMAN			23	270
DLG1 PDZ2	DKKITTV	13	9	22	EXOC4_HUMAN	Bolis et al. (14)	19587293	24	451
DLG1 PDZ2	VQRHTWL	15	3	18	NXPE2_HUMAN			25	33
DLG1 PDZ2	DRKETSI	8	9	17	RBP1_HUMAN			26	70
DLG1 PDZ2	TSRETDL	13	0	13	KCNA5_HUMAN	Mathur et al. (15)	16466689	27	4
DLG1 PDZ2	KAVETDV	5	5	10	KCNA4_HUMAN	Kim et al. (16)	7477295	28	9
DLG1 PDZ2	YRRESEI	7	0	7	IRK12_HUMAN	Leonoudakis et al. (17)	14960569	29	267
DLG1 PDZ2	ASPDSWV	1	6	7	CTND2_HUMAN			30	429
DLG1 PDZ3	LRKETRV	146285	89,316	235,601	CLTR2_HUMAN	Gfeller et al. (3)	21525870	1	2
DLG1 PDZ3	NYKQTSV	287	622	909	CRIPT_HUMAN	Cai et al. (18)	12070168	2	1
DLG1 PDZ3	KRKETLV	18	4	22	ARHG8_HUMAN	Carr (6)	19586902	3	5

Library A and Library B, the sequencing counts for a given peptide from the replicate selection; Peptide, the selected C-terminal peptides; Protein, the identity of the bait PDZ domain; Rank ProP-PD, the rank of a peptide based on the selection (1: sequence with the highest total sequencing counts); Rank Tonikian PWM, predicted rank of a selected peptide using position specific scoring matrices based on the data of Tonikian et al. (18) among all sequences in the designed human ProP-PD library Reference, reference to a supporting publication with Pubmed id in PMID; Total, total sequencing counts of a given peptide; Uniprot, the Uniprot entry corresponding to a selected peptide.

1. Audebert S, et al. (2004) Mammalian Scribble forms a tight complex with the betaPIX exchange factor. Curr Biol 14(11):987–995.

2. Zhang Y, et al. (2006) Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families. J Biol Chem 281(31):22299–22311.

3. Gfeller D, et al. (2011) The multiple-specificity landscape of modular peptide recognition domains. Mol Syst Biol 7:484.

4. Izawa I, et al. (2002) Densin-180 interacts with delta-catenin/neural plakophilin-related armadillo repeat protein at synapses. J Biol Chem 277(7):5345–5350.

5. Laura RP, et al. (2002) The Erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of delta-catenin and ARVCF. J Biol Chem 277(15):12906–12914.

6. Izawa I, et al. (2002) ERBIN associates with p0071, an armadillo protein, at cell-cell junctions of epithelial cells. J Biol Chem 277(15):12906–12914.

7. Carr HS, et al. (2009) Interaction of the RhoA exchange factor Net1 with discs large homolog 1 protects it from proteasome-mediated degradation and potentiates Net1 activity. J Biol Chem 284(36):24269–24280.

9. Yamamoto Y, et al. (2004) Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein. Oncogene 23(22):3889–3897.

10. Huang YZ, et al. (2002) Compartmentalized NRG signaling and PDZ domain-containing proteins in synapse structure and function. Int J Dev Neurosci 20(3-5):173–185.

11. Inanobe A, et al. (2002) Inward rectifier K+ channel Kir2.3 is localized at the postsynaptic membrane of excitatory synapses. Am J Physiol Cell Physiol 282(6):C1396–1403.

12. Petitprez S, et al. (2011) SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes. Circ Res 108(3):294–304.

13. Lee HW, et al. (2008) Preso, a novel PSD-95-interacting FERM and PDZ domain protein that regulates dendritic spine morphogenesis. J Neurosci 28(53):14546–14556.

14. Bolis A, et al. (2009) Dlg1, Sec8, and Mtmr2 regulate membrane homeostasis in Schwann cell myelination. J Neurosci 29(27):8858-8870.

15. Mathur R, et al. (2006) A specific N-terminal residue in Kv1.5 is required for upregulation of the channel by SAP97. Biochem Biophys Res Commun 342(1):1-8.

16. Kim E, et al. (1995) Clustering of Shaker-type K+ channels by interaction with a family of membrane-associated guanylate kinases. Nature 378(6552):85–88.

17. Leonoudakis D, et al. (2004) A multiprotein trafficking complex composed of SAP97, CASK, Veli, and Mint1 is associated with inward rectifier Kir2 potassium channels. J Biol Chem 279(18):19051–19063.

18. Tonikian R, et al. (2008) A specificity map for the PDZ domain family. PLoS Biol 6(9):e239.

Table S2. Comprehensive list of identified viral targets stating interacting PDZ domains, peptide sequences, sequencing counts, and literature reference, when applicable

							Source (for the protein,	
Protein	Pentide	Count A	Count B	Total	Uniprot	Name	not always the exact variant)	PMID
		count A	21 596	21 506			Nakagawa	11027202
SCHOOLE PDZ1	RREIAL	x	21,500	21,300	VE0_HPV35	type 33 protein E6	and Huibregtse (1)	11027295
Scribble PDZ1	TRRETQL	х	175	175	VE6_HPV16	Human papillomavirus	Nakagawa	11027293
Scribble PDZ1	PDTDWLV	x	62	62	LRP2 HHV1F	type 16 protein E6 Human herpesvirus 1	and Hulbregtse (1)	
					_	latency-related protein 2		
Scribble PDZ2	HFREIEV	3,827	49,903	53,/30	IAX_HIL1F	virus 1 protein Tax-1	Arpin-Andre and Mesnard (2)	1/8553/2
Scribble PDZ2	HFHETEV	26	474	500	TAX_HTL1L	Human T-cell leukemia	Arpin-André and Mesnard (2)	17855372
Scribble PDZ3	RRRETAL	118,682	69,771	188,453	VE6 HPV33	Human papillomavirus	Nakagawa	11027293
	TRAFTO	20 722	20.067	50.000		type 33 protein E6	and Huibregtse (1)	44007000
Scribble PDZ3	TRRETQL	28,733	29,867	58,600	VE6_HPV16	type 16 protein E6	and Huibregtse (1)	11027293
Scribble PDZ3	HFRETEV	110	589	699	TAX_HTL1F	Human T-cell leukemia	Arpin-André (2)	17855372
Scribble PDZ3	TRRETEV	81	130	211	VE6 HPV35	virus 1 protein Tax-1 Human papillomavirus	Nakagawa	11027293
						type 35 protein E6	and Huibregtse (1)	
Scribble PDZ3	TRRETQV	39	145	184	VE6_HPV39	Human papillomavirus	Nakagawa and Huibregtse (1)	11027293
Scribble PDZ3	AIFSTDI	1	81	82	YVDA_VACCW	Vaccinia virus uncharacterized		
Scribble DD72	SCOTTRI	2	75	77		9.2 kDa protein		
Scribble PDZ3	TGRSTTL	2	64	72	VGLG_KABVV	Sheeppox virus putative		
						fusion protein		
Scribble PDZ3	IRRETQV	24	41	65	VE6_HPV70	Human papillomavirus	Nakagawa and Huibreatse (1)	11027293
Scribble PDZ3	RRRETQV	2	61	63	VE6_HPV45	Human papillomavirus	Nakagawa	11027293
Scribble PD73		6	20	45		type 45, protein E6 Human T. coll Joukomia	and Huibregtse (1)	18661220
SCIDDLE FDZS	HEHEV	0	29	45	TAA_HILIL	virus 1 protein Tax-1	Okajima et al. (5)	10001220
Scribble PDZ3	PFSSSDL	4	15	19	GAG_MLVAB	Abelson murine leukemia		
Scribble PDZ3	LNYETNL	1	13	14	ENV_HTL3P	Human T-cell leukemia		
						virus 3 envelope		
Frhin		7	3 235	3 242	VEMP ВСНКА	glycoprotein gp63 Bat coronavirus Envelope		
		,	5,255	5,242	VEINI _DCI IIC4	small membrane protein		
Erbin	YPPEDWV	5	699	704	VEMP_BCHK5	Bat coronavirus Envelope		
Erbin	RRRETAL	4	407	411	VE6_HPV33	Human papillomavirus		
Frhin		2	210	221		type 33 protein E6		
Erdin	DKLDINVVV	2	319	321	VPU_HVIYB	protein Vpu		
Erbin	IDQDNWV	4	220	224	VPU_SIVEK	Simina immunodeficiency		
Erbin	TRRETQL	0	168	168	VE6 HPV16	virus protein Vpu Human papillomavirus		
					_	type 16 protein E6		
Erbin	ATCTFTL	2	106	108	VP23_ELHVK	Elephantid herpesvirus 1, triplex capsid protein U56		
Erbin	IRRETQV	6	92	98	VE6_HPV70	Human papillomavirus		
Frhin	ΔΤΗΙ ΙΝΙΔ	5	83	88	11021 ASEW/A	type 70, protein E6 African swine fever virus		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	5	05	00	11022_/01107	protein MGF 110–2L		
Erbin	APSVLTV	2	80	82	NS3D_BCHK5	Bat coronavirus KHU5		
Erbin	AVNFSTL	1	74	75	OBP_HHV2H	Human herpesvirus 2 replication		
Frhin	HEBETE//	0	7/	7/	TAX HTI 15	origin-binding protein	Song et al. (1)	10/77101
		U	/4	/4		protein Tax-1	Jong et al. (4)	1,5412131
DLG1 PDZ1	IRRETQV	283	539	822	VE6_HPV70	Human papillomavirus type 70,	Gardiol et al. (5)	10523825
DLG1 PDZ1	TRRETQV	406	132	538	VE6_HPV39	Human papillomavirus type 39 protein E6	Gardiol et al. (5)	10523825

PNAS PNAS

Protein	Peptide	Count A	Count B	Total	Uniprot	Name	Source (for the protein, not always the exact variant)	PMID
DLG1 PDZ2	IRRETQV	102,877	71,200	174,077	VE6_HPV70	Human papillomavirus type 70. protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	TRRETQV	17,861	24,016	41,877	VE6_HPV39	Human papillomavirus type 39 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	TRRETEV	4,089	4,716	8,805	VE6_HPV35	Human papillomavirus type 35 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	TGRSTEV	1,223	6,115	7,338	VU47_HHV6U	Human herpesvirus 6A glycoprotein U47	Blot et al. (6)	15286176
DLG1 PDZ2	RRRETQV	2,679	4,196	6,875	VE6_HPV18/45	Human papillomavirus type 18/45 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	RGIESEV	329	1,321	1,650	NS1_I63A1	Influenza A virus (Avian) nonstructural protein 1	Liu et al. (7)	20702615
DLG1 PDZ2	RRRETAL	382	706	1,088	VE6_HPV33	Human papillomavirus type 33 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	HFRETEV	100	534	634	TAX_HTL1F	Human T-cell leukemia virus 1 protein Tax-1	Lee et al. (8)	9192623
DLG1 PDZ2	TRRETQL	175	359	534	VE6_HPV16	Human papillomavirus type 16 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	TRQETQV	22	323	345	VE6_HPVME	Human papillomavirus type ME180 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	IRQETQV	46	293	339	VE6_HPV68	Human papillomavirus type 68 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	RHRETYV	25	133	158	US32_HCMVA	Human cytomegalovirus, uncharacterized protein HHRF7		
DLG1 PDZ2	PRTETQV	9	139	148	VE6_HPV31	Human papillomavirus type 31 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	RQTETQV	8	101	109	VE6_HPV26	Human papillomavirus type 26 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	QRNETQV	24	72	96	VE6_HPV51	Human papillomavirus type 51 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	RRIESEV	3	22	25	NS1_I49A1	Influenza A virus (Avian) nonstructural protein 1	Liu et al. (7)	20702615
DLG1 PDZ2	RRVESEV	3	18	21	NS1_I82A8	Influenza A virus (Avian) nonstructural protein 1	Liu et al. (7)	20702615
DLG1 PDZ2	RRRQTQV	0	11	11	VE6_HPV58	Human papillomavirus type 58 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ2	TGRSTTL	1	9	10	VFUS_SHEVK	Sheeppox virus putative fusion protein		
DLG1 PDZ3	IRRETQV	61,437	31,152	92,589	VE6_HPV70,	Human papillomavirus type 70, protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ3	TRRETQV	19,459	10,283	29,742	VE6_HPV39,	Human papillomavirus type 39 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ3	RRRETQV	2,336	8,525	10,861	VE6_HPV45,	Human papillomavirus type 18/45 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ3	RRRETAL	1,213	1,297	2,510	VE6_HPV33,	Human papillomavirus type 33 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ3	TRRETEV	90	227	317	VE6_HPV35,	Human papillomavirus type 35 protein E6	Gardiol et al. (5)	10523825
DLG1 PDZ3	RHRETYV	26	49	75	US32_HCMVA	Human cytomegalovirus, uncharacterized protein HHRF7		

Column labels are as in Table S1, plus a "Name" describing the protein and virus.

1. Nakagawa S, Huibregtse JM (2000) Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20(21):8244–8253.

2. Arpin-André C, Mesnard JM (2007) The PDZ domain-binding motif of the human T cell leukemia virus type 1 tax protein induces mislocalization of the tumor suppressor hScrib in T cells. J Biol Chem 282(45):33132–33141.

3. Okajima M, et al. (2008) Human T-cell leukemia virus type 1 Tax induces an aberrant clustering of the tumor suppressor Scribble through the PDZ domain-binding motif dependent and independent interaction. Virus Genes 37(2):231–240.

4. Song C, et al. (2009) Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway. IUBMB Life 61(6):685–692.

 Gardiol D, et al. (1999) Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18(40):5487–5496.
Blot V, et al. (2004) Human Dlg protein binds to the envelope glycoproteins of human T-cell leukemia virus type 1 and regulates envelope mediated cell-cell fusion in T lymphocytes. J Cell Sci 117(Pt 17):3983–3993.

7. Liu H, et al. (2010) The ESEV PDZ-binding motif of the avian influenza A virus NS1 protein protects infected cells from apoptosis by directly targeting Scribble. J Virol 84(21):11164–11174.

8. Lee SS, Weiss RS, Javier RT (1997) Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 94(13):6670–6675.

## Table S3. Selected peptides of low interest to this study

PDZ domain	Peptide	Protein	# Library A	# Library B	Total count
Additional target pe	ptides from the prote	olytic TopFind set			
Scribble PDZ1	DRDYMGW	CCKN_HUMAN, CLEAVAGE-8141	343	0	343
Scribble PDZ2	GFYESDV	A2MG_HUMAN CLEAVAGE-593	1	328	329
Scribble PDZ3	GFYESDV	A2MG_HUMAN CLEAVAGE-593	0	242	242
Scribble PDZ3	WTTSTDL	AMPH_HUMAN INFERRED FROM	1,823	62	1,885
		CLEAVAGE-4706			
Additional target pe	ptides from the ENSEM	/IBL-only set			
Scribble PDZ1	KTYETDL	ENSP00000447314	1,326	56	1,382
Scribble PDZ3	KTYETDL	ENSP00000447314	2,224	12,398	14,622
Scribble PDZ3	LLRETSL	ENSP00000420911	97	0	97
Scribble PDZ3	VSRETKL	ENSP00000415771	0	85	85
Scribble PDZ3	GIRESKL	ENSP00000399301	0	79	79
Scribble PDZ3	GVRKETA	ENSP00000451805	0	20	20
Scribble PDZ3	FSEGTDL	ENSP00000440057	0	10	10
Scribble PDZ3	AGKTTIL	ENSP00000450315	0	8	8
Erbin	QENDWWV	ENSP00000398110	28,359	1,117	29,476
Erbin	QHHWESW	ENSP00000270281	0	40	40
DLG1 PDZ2	FPKETQV	ENSP00000442101	0	2,275	2,275
DLG1 PDZ2	SGTAYLL	ENSP00000449745	8	7	1

The peptides correspond to protein C termini either only supported by an experiment in TopFind (resulting from proteolytic cleavage or COFRADIC-based complementary positional proteomics experiments) or only found in ENSEMBL. PDZ domain, the identity of the bait PDZ domain; Peptide, the selected C-terminal peptides; Protein, the identifier corresponding to a selected peptide and the cleavage site when applicable; # Library A and # Library B, the sequencing counts for a given peptide from the replicate selection.

## **Other Supporting Information Files**

Dataset S1 (XLSX) Dataset S2 (XLSX)

SANG SANG